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Abstract 
Selenium (Se) is an essential micronutrient element linked to many biological functions 
in human health (1).  Two proteins involved in Se metabolism are Selenoprotein P (Sepp1) and 
Selenocysteine lyase (Scly).  Previous studies in our lab showed that when both Sepp1 and Scly 
were disrupted, male double knockout Se-supplemented mice (MDKOSe) exhibited decreased 
survival, severe neurological impairment and susceptibility to audiogenic seizures (AGS) (2).   
Further investigation indicates that between 70 and 80% of MDKOSe mice will develop 
seizure characteristics between 8 and 12 weeks of age, with about 40% requiring euthanasia prior 
to 10 weeks.  A significant decrease in motor coordination starting around 6 weeks of age along 
with wobbly or abnormal gait precedes seizure development.  Seizures occur within a week of 
weight loss commencement, accompanied by a decrease in food and water intake.  Female 
DKOSe mice have decreased motor coordination starting at 7 weeks of age and increased 
percentage of inguinal and gonadal white adipose tissue fat deposits and elevated serum 
glutathione peroxidase 3 levels.  The neurological deficit becomes severe, leading to seizure 
development if high selenium supplementation is removed at weaning.   
  Disruption of the maturation of GABAergic inhibition seems to be the main neurological 
effect leading to the development of AGS in MDKOSe mice.  Preadolescent castration rescues 
the MDKOSe phenotype.  It delays onset of neuromotor deficits in male Sepp1 knockout mice 
on a Se deficient diet and is protective of male wild type mice exposed to the neurotoxin 
dizocilpine maleate (MK-801).   Testosterone re-administration to sham-operated MDKOSe 
mice appears to be beneficial but not preventative.   
  Together, these results indicate that there is a critical time point in which Se is essential 
for the prevention of neurological impairment in both female and male DKOSe mice.  MDKOSe 
may have a greater need for Se during the course of their sexual reproductive period due to 
competition between the testes and the brain for Se.  The specific deficits in behavioral tests and 
underlying GABAergic system maturation disruption could allow DKOSe mice to potentially 
serve as a model for the study of ictogenesis and therapeutic drug testing of novel drugs for 
epileptic patients.   
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Chapter 1: Selenium – the Micronutrient 
Introduction 
Selenium (Se) was first discovered by Jöns Jacob Berzelius in 1817 when he identified it 
as the toxic element causing illness in Swedish plant workers (3).  For years, it was studied due 
to its connection with livestock.  Se toxicity in livestock leads to lameness, emaciation, and other 
detrimental conditions.  Deficiency results in what has been called “white muscle disease” due to 
the white appearance of dying cell membranes in heart and skeletal muscles (3; 4).  It was not 
until 1957 that the nutritional value of Se was recognized in the diet of rats (5).  Later, in 1969, 
the role of Se as an essential micronutrient was established through a study of dietary deficiency 
in multiple rat generations (6).  Se in the form of selenocysteine (Sec) was found to be a key 
component of glutathione peroxidase (Gpx), which is essential in the body’s defenses against 
oxidative stress (7). 
Since then, Se has been linked to many biological functions in human health including 
thyroid hormone synthesis and antioxidant stress defense (1).  Whereas Se toxicity leads to 
musculoskeletal disorders (alterations in cartilage) (8), Se deficiency has been linked to clinical 
disorders such as Keshan disease (a cardiomyopathy) and Kashin-Beck disease (degenerative 
osteoarthropathy) (1) and low Se levels have been indicated in febrile seizures (9; 10; 11).  
Genetic mutations in genes related to Se metabolism have been shown to cause congenital 
muscular dystrophy (Selenoprotein N defect), progressive cerebello-cerebral atrophy (SEPSECS 
mutation) and retarded growth (SEC1SBP2 Syndrome) (12).   
As an essential micronutrient, Se is acquired through dietary intake.  Plants are the main 
source of Se for humans.  Se accumulation in plants is dependent on soil Se (13; 14) and local 
climate factors such as precipitation and seasonal weather variation play key roles in Se soil 
distribution (7; 15).  Globally, it is estimated that half a billion to one billion people are Se 
deficient (15; 16) and this is predicted to increase in the future due to local climate factors (17). 
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Figure 1.1: Selenium Dietary Intake Recommendations.  Selenium dietary intake of adults (top) 
and children ages 0-13 years of age (bottom) (7; 18; 19). 
 
The recommended dietary intake for Se varies depending on a person’s stage of 
development.  For adults, the daily recommendation is 55-70 µg/day with an upper tolerant limit 
of 400 µg/day.  Clinical signs of toxicity are seen when intake reaches around 750 µg/day (18; 
20).  In children, the recommended Se intake and toxicity levels rely heavily on developmental 
stage with recommended intake varying between 15-40 µg and upper limits of 45-280 µg (Figure 
1).   
In mammals, adequate nutrient intake is a key factor in maintaining health and is 
important for normal growth and development.  Although there are general guidelines for daily 
nutritional requirements, it has become evident that other factors (e.g. genetics, sex, and age) can 
alter an individual’s nutritional needs.  Malnutrition at key points of development can lead to 
long-term effects and chronic disease (21; 22; 23; 24).  The FAO reported in 2004 that 
malnutrition affects about 852 million people worldwide (25).  In a more recent 2015 release, it 
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was estimated that about 777 million people worldwide are chronically undernourished (26) and 
according to the 2015 WHO Global Health 
Estimates report, nutritional deficiencies account 
for about 1% of deaths worldwide (27).  In 
children, it is estimated that malnutrition 
contributes to close to 5 million deaths per year 
and causes an additional 182 million to be 
physically and cognitively stunted (24).  
Investigation into the role of specific nutrients 
and the physiological pathways affecting key life 
stages is necessary to provide clinical targets that 
may help alleviate this global burden. 
Of the elements listed on the periodic 
table, nineteen elements, including Se, are 
considered to be essential in the human diet to 
provide adequate nutrition.  In the US, eight are 
recognized as “trace” elements (micronutrients hereafter) (18) as they are required in very small 
amounts (Table 1.1).  Micronutrients tend to have narrow biological therapeutic ranges and 
excess can lead to toxicity in humans, as is the case with Se.   
In the last decade, there has been a shift in how malnutrition is viewed.  It is evident that 
inadequate micronutrient intake can lead to metabolic disruption and DNA damage (28; 29; 30; 
31; 32).  This has been particularly important in the raising of livestock as food sources.  In 
cattle, even though the epigenome of an animal is heritable, it can be modified by diet (29; 32) 
giving insight into a possible application of “personalized nutrition” in both animals and humans 
(21).  With advancements in genomic sequencing and studies in epigenetics, it may be that in the 
future clinical providers can match nutritional supplementation recommendations to a person’s 
current genomic and environmental status thereby optimizing the body’s ability to remain 
healthy and fight physical ailments. 
 
 
 
Table 1.1: Current FDA Recommendations 
for Daily Micronutrients Intake (18). 
Element 2017 FDA 
Recommended 
Daily Amount 
Iron (Fe) 18 mg 
Zinc (Zn) 15 mg 
Copper (Cu) 2 mg 
Manganese (Mn) 2 mg 
Iodine (I) 150 μg 
Chromium (Cr) 120 μg 
Molybdenum (Mo) 75 μg 
Selenium (Se) 70 μg 
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Selenium absorption and metabolism 
The complete pathway of Se absorption and metabolism in the body has yet to be 
determined.  It has been reported that Se can be obtained through dietary means in either organic 
forms, i.e. selenomethionine or selenocysteine, or inorganic forms, i.e. selenite, SeO3-2; selenide, 
Se-2; selenate, SeO4-2; and elemental Se (8).  Se can be incorporated into proteins by either 
specific mechanisms, i.e. selenoproteins, or non-specific mechanisms, i.e. replacement of sulfur 
(Figure 1.2) (1; 33; 34).  Selenide (H2Se) is believed to be a central component that can lead 
either to selenoprotein formation or Se excretion (respiratory, urine, or feces).  Mechanisms of 
Se absorption from diet depend on the form received.  Inorganic Se can be processed by simple 
diffusion or co-transport and exchange, whereas organic Se processing is through incorporation 
into the amino acids, selenocysteine or selenomethionine.  Se compounds have been shown to be 
taken up by erythrocytes (e.g. selenite) and bind to albumin (e.g. selenide) as well as α and β 
globulins, low density lipoprotein (LDL) and very low density lipoprotein (VLDL) (8). 
When dietary Se is deficient, the body compensates through increasing metabolites which 
are capable of acting as antioxidants.  Metabolites involved in one-carbon metabolism leading to 
glutathione production are altered in Se deficiency as indicated by increased levels of serine, 
glycine, and threonine along with dysregulation of the methionine-homocysteine cycle (35).  
These can potentially cause changes in redox-methylation, lipid head group formation, and DNA 
methylation (35; 36; 37; 38).  Se deficiency also alters phenylalanine, tyrosine, and tryptophan 
biosynthesis (35) which can affect levels of dopamine, norepinephrine or epinephrine, and 
thyroid hormones (39).   
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Figure 1.2: Selenium Absorption and Metabolism.  Summary schematic of Se absorption and 
metabolism as determined from multiple studies using human tissue and rat and mouse animal 
models (1; 34; 40; 41).   
 
Selenium distribution in the body 
Se tissue distribution and concentrations vary with age and diet.  With adequate dietary 
Se, the biological trend is that the highest concentrations are found in the kidney and liver and 
the lowest in the brain and lung.  In humans, the muscle has the highest percentage of total body 
Se, ranging from 27% to 50%, whereas the liver accounts for approximately 7%, the kidney ~2-
4%, and the brain ~2.5% (42; 43; 44; 45). 
When rats were fed a diet deficient in Se, Se was preferentially retained in the brain, 
pituitary, thyroid, ovaries, adrenal glands, and testes (46; 47), with the brain given priority at the 
expense of other organs (47; 48; 49; 50).  In the rat brain, the highest concentrations of selenium 
are found in the gray matter (45), including the cerebellum, and the lowest concentrations are 
found in the brain stem (50; 51; 52).  Subcellular distribution of Se is highest in synaptosomal 
and mitochondrial areas (51). 
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Selenium, the element 
The element Se is characterized as a metalloid resembling sulfur in chemical terms.  It 
has six isotopes that occur naturally in both organic and inorganic forms.  In humans, it is 
generally accepted that most or all of the biological functions of Se are manifested by its 
presence in the 21st amino acid, Sec.  Sec is structurally analogous to cysteine (Cys), with Se in 
place of sulfur.  However, Sec is not derived from Cys, but is synthesized on the carbon 
backbone of serine (Figure 1.3).  Sec is then incorporated into 30 selenoproteins (53), encoded 
by one of 25 known genes (1).   
Most selenoproteins incorporate Sec in their catalytic sites.  Many studies have been 
conducted on the chemical properties that change when sulfur is replaced by Se (reviewed by 
Arner in 2010).  Se has a higher nucleophilicity than its analog, Cys.  This potentially allows it to 
yield faster reaction rates at physiological pH than, with higher redox potentials in non-
equilibrium states (54). 
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Figure 1.3: Selenocysteine (Sec) Biosynthesis and Incorporation.  Serine (Ser) is 
aminoacylated with special tRNA[Ser]Sec by Ser-tRNA synthase.  Ser is then 
phosphorylated by phosphoseryl-tRNA kinase to yield pSer-tRNA[Ser]Sec.   pSer-
tRNA[Ser]Sec  is then converted to Sec by the enzyme selenocysteine synthase which uses a 
selenophosphate as the Se donor producing Sec-tRNA[Ser]Sec.  Sec is then incorporated into 
the elongating selenoprotein.  During selenoprotein synthesis, Sec-tRNA[Ser]Sec insertion 
occurs at UGA codons when directed by SECIS elements within selenoprotein mRNAs.  
 
 
Selenide 
(H2Se) 
Selenoproteins
Serine 
(Ser) 
Ser-tRNA
Synthase
Phosphoseryl-tRNA
Kinase 
pSer-tRNA[Ser]Sec
Ser-tRNA[Ser]Sec
Selenocysteine 
Synthase 
Selenophosphate
(SePO3H3)
Selenophosphate
Synthatase
Sec-tRNA[Ser]Sec
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Selenium and the brain 
The roles of the micronutrient Se in brain development and function have become of 
increasing interest.  Sec is incorporated into proteins involved in growth, development, and 
antioxidant defense systems.  These proteins include iodothyronine deiodinases (Dios), 
glutathione peroxidases (Gpxs) and thioredoxin reductases (Txrnds). 
Iodothyronine deiodinases (Dios) catalyze activation and inactivation of thyroid 
hormone, which functions in many aspects of development and body homeostasis.  The two 
predominant brain deiodinases are Dio2 and Dio3.  Dio2, an endoplasmic reticulum (ER) 
anchored enzyme with its catalytic site exposed to the lumen, is predominately found in 
astrocytes, where it activates the thyroid prohormone 3, 5, 3’,5’,-tetraiodothyronine (T4) via 
conversion to the active hormone, 3, 5, 3’-triiodothyronine (T3).  Knockout of Dio2 can lead to a 
hypothyroid state causing changes in bone and muscle, and in carbohydrate and lipid metabolism 
(55).  Hypothyroidism during critical periods of development can lead to cognitive and 
behavioral dysfunction (56).  It can also delay neuronal differentiation (57) and lead to an age-
dependent development of ataxic gait and severe cretinism (58). 
Dio3 is a plasma membrane anchored selenoprotein found in neurons and important in 
thyroid hormone metabolism.  In the brain, it inactivates T4 and T3 by converting them to 
reverse 3, 3’, 5’-triiodothyronine (rT3) and 3, 3’-diiodothyronine (T2), respectively.  In mice, 
Dio3 is highly expressed during the first week after birth, then diminishes rapidly thereafter (59).  
Dio3 has been found highly expressed in areas of sexual differentiation in rat neonates (60).  The 
lack of Dio3 produces a thyrotoxicosis state in mouse neonates, followed by a central 
hypothyroidism state at postnatal day 15, indicating its importance in thyroid axis development 
(59).  It has been reported that there is a “hypo-responsive” period where mammals are unable to 
respond to stress hormones (61).  This corresponds to the time when Dio3 is highly expressed.  
Other studies have linked transient hypothyroidism in neonatal animals to the development of 
audiogenic seizures in adults, with onset at puberty (62; 63).   
Dio3 expression is stimulated by T3 levels.  T3 has been shown to be upstream of p38, 
mitochondria biogenesis, AKT signaling, PI3K/ERK, and mTOR, thereby increasing metabolism 
and oxygen consumption (60).  Dio3 inactivates T3 and therefore decreases the metabolic rate.  
Other pathways, including TGFB3, FGF, and HIF1α, also activate Dio3, resulting in reduced 
metabolic rate and oxygen consumption and increased β-oxidation (64).  
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The Gpxs and Txnrds have important roles in antioxidant defense.  The brain has a very 
high energy requirement, accounting for over 70% of total body energy consumption in 
newborns and 20-30% in adults (65).  The brain runs almost exclusively on glucose with 
glycogen being a short-term energy reserve.  As a backup, the brain relies on ketones with fatty 
acid oxidation releasing twice as much energy as glycogen.  Though not a requirement in adults, 
ketones are required during infancy, with uptake being 3 to 5 times faster in newborns (66).  
Ketones provide the main carbon source for brain cholesterol and long-chain fatty acids of 
structural lipids in development (65).   
With a high metabolic rate comes the need for antioxidant defense.  Se incorporation into 
the structure of Gpx was the key finding that confirmed its role as an essential micronutrient (7).  
Gpx utilizes glutathione as a co-factor in the reduction of hydrogen peroxide and phospholipid 
hydroperoxides, thereby neutralizing oxidative stress.  Sec is incorporated into five of the eight 
Gpxs (67); Gpx1, Gpx2 (gastrointestinal), Gpx3 (plasma), Gpx4 and Gpx6 (olfactory).  Of the 
five, Gpx1 is the most abundant, is found in the cytoplasm in mammalian tissues and catalyzes 
the reduction of hydrogen peroxide to water.  Deletion of Gpx1 in mice revealed sensitivity to 
oxidative stress-inducing agents (68) whereas overexpression has been shown to modulate 
damage to long-term memory resulting from traumatic brain injury (69).   
Gpx4 is essential for early development; it is the only Gpx whose deletion results in 
embryonic lethality (70).  Gpx4 reduces phospholipid hydroperoxides, distinguishing this 
isoform from the other Gpxs.  In the brain, Gpx4 is expressed in neurons but can be found 
upregulated in astrocytes in pathological states (71).  Its mRNA can be detected in all stages of 
brain development, with regional distribution during embryogenesis (71).  It has three isoforms, 
mitochondrial, cytosolic, and nuclear.  The mitochondrial form (Gpx4-mt) appears to be 
important for normal brain development, as selective deletion impairs formation of the hindbrain 
(72).   Mice with a conditional knockout of Gpx4 in neurons have decreased parvalbumin 
positive interneurons (PV+IN), a subpopulation of inhibitory, GABAergic interneurons which act 
to synchronize neural activity, and levels are decreased in Se deficient mice that develop 
audiogenic seizures (2). 
Gpx4 is also crucial for male fertility in mammals.  The testes have a high concentration 
of Se (73) and male rats deprived of Se over two generations become infertile (6).  At the 
beginning of spermatogenesis, Se in the testes begins to accumulate in high molecular weight 
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protein aggregates that were shown to be composed of highly cross-linked, enzymatically 
inactive Gpx4 (73).  This is believed to be due to the essential role of Gpx4 as part of mid-piece 
of sperm (73; 74; 75; 76; 77) with lack thereof leading to sperm abnormalities (78) resulting in 
reduced fertility.   
Thioredoxin reductases (Txnrds) are involved in cellular redox balance, cell signaling and 
DNA synthesis indirectly via their role in thioredoxin (Txn) reduction (79).  Sec is incorporated 
into their C-terminal domains where it acts in electron transport to reduce Txn and prevents 
Txnrds from acting as glutathione reductase (GR) (80).  Two Txnrds are ubiquitously expressed, 
Txnrd1 in the cytosol and Txnrd2 in the mitochondria.  The third, a thioredoxin-glutaredoxin 
reductase, Txnrd3 resides in the testes.  Similar to GR, Txnrds utilizes NADPH to reduce Txn 
but Txn is not their only target.  Txnrds have the ability to directly reduce Txn along with other 
non-disulfide substrates e.g. selenite, hydrogen peroxide and lipid hydroproxides.  This broad 
substrate specificity is what separates them from GR (81).  When globally deleted, both Txnrd1 
and 2 are embryonic lethal.  Nervous system-specific knockout of Txnrd1 leads to growth 
retardation with ataxia and cerebellar hypoplasia due to decreased proliferation of granule cell 
precursors, whereas Txnrd2 knockout shows no obvious pathology (79).  This evidence suggests 
Txnrd1 is more important in cerebellar development than Txnrd2. 
 
Proteins important for selenium metabolism 
Several reviews have been published on selenoproteins and their known functions to date 
(34; 45; 67; 74; 82; 83).  The following chapters focus on two proteins important to Se 
metabolism, selenoprotein P (Sepp1), implicated in Se transport and storage, and selenocysteine 
lyase (Scly), involved in selenocysteine breakdown and recycling.  Sepp1 is a plasma 
glycoprotein that consists of two domains, an N-terminal domain containing a redox motif and a 
C-terminal domain containing multiple Sec residues.  It accounts for about 60% of the Se 
concentration in the plasma and is believed to be the major transporter of Se from liver to other 
tissues (84).  Although plasma Sepp1 is secreted mostly by the liver (40), its mRNA is expressed 
in many tissues including kidney, heart, lung, skeletal muscle, brain, and testis (85; 86).   
In Sepp1 knockout mice (Sepp1KO), both Se and Gpx activity levels are reduced in the 
brain and testes, indicating Sepp1 is important to both of these tissues for Se supply.   Brain Se 
levels have been shown to be independent of plasma Se levels as long as there is local expression 
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of Sepp1 (40), whereas Sepp1KO combined with a Se deficient diet results in neurological 
dysfunction and male infertility (73; 78; 87; 88).  A diet of 0.25 ppm largely prevents 
neurological dysfunction (87) but even with an Se adequate diet, Sepp1KO mice still exhibit 
deficits in contextual fear extinction, latent inhibition, and sensorimotor gating (89).  A high Se 
diet of 1 ppm does not seem to reverse this, as mice on this diet still exhibit deficits in motor 
coordination and spatial learning, and altered hippocampus synaptic transmission and plasticity 
(90).   
Apolipoprotein E receptor-2 (ApoER2) is the primary receptor for Sepp1 in the brain and 
testes.  Similar to Sepp1KO, mice lacking ApoER2 have diminished Se levels in brain and testes 
with resulting infertility.  They exhibit neurological dysfunction and neurodegeneration in 
auditory and motor areas of the brain when fed a Se-deficient diet (91; 92; 93).  ApoER2 
knockout mice also exhibit impaired hippocampal synaptic plasticity and cognitive deficits (94).  
Together, these studies indicate the importance of Sepp1 in supplying Se to the brain via 
ApoER2, to prevent neurological dysfunction.   
Scly has been shown to selectively catalyze the breakdown of Sec into L-alanine and 
selenide (H2Se) allowing Se to be recycled for additional selenoprotein synthesis (95).  Scly, a 
homodimeric enzyme found in most tissues, exhibits high activity in the liver and kidneys, and is 
undetectable in blood and fat (96).  It is necessary for balance in energy metabolism, specifically 
lipid and glucose metabolism, under conditions of dietary Se deficiency (83; 97).  Scly knockout 
mice (SclyKO) fed a Se adequate diet develop normally without neurobehavioral deficits, and 
both male and female mice are fertile (83).  When fed a Se deficient diet, fat accumulation 
becomes apparent as the mice age, which leads to a metabolic syndrome phenotype (97) that is 
more pronounced in males.  SclyKO mice on an Se deficient diet also develop mild deficits in 
spatial learning (83). 
When both Sepp1 and Scly are deleted, mice require supplementation with high Se levels 
to survive past weaning.  They have severe neurological impairments with reduced motor 
coordination and increased susceptibility to audiogenic seizures (AGS), and exhibit 
neurodegeneration in the brainstem (2).  They also show signs of GABAergic system defects 
with reduced density of PV+IN and GAD67, an enzyme that converts glutamate to inhibitory 
neurotransmitter, GABA.  This phenotype was more pronounced in the males as female mice, on 
the same diet, have a milder motor deficit and do not appear to develop AGS (2).   
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Conclusion 
In summary, Se is a micronutrient linked to many biological functions in human health.  
Its biological action is through its incorporation via Sec into selenoproteins involved in growth, 
development and antioxidant defense systems, e.g. Gpxs, Txnrds, and Dios.  When Se is 
deficient in the diet, it is preferably retained in the brain at the expense of other organs 
highlighting the importance of Se as a micronutrient for this organ.  Two proteins involved in Se 
metabolism are Selenoprotein P (Sepp1) and Selenocysteine lyase (Scly).  Sepp1 is involved in 
Se transport, whereas Scly catalyzes the breakdown of Sec, allowing Se to be recycled for 
additional selenoprotein synthesis.  Though knowledge of the nutritional value of Se has 
expanded over the last 200 years, the biological functions and mechanisms of action of 
selenoproteins have yet to be fully understood.  Further investigation into the roles of 
selenoproteins at key points of development would be beneficial in determining dietary 
supplementation requirements.  This knowledge can then be used to optimize individualized 
nutrition in both humans and animals, thereby having potential application to prevent disease 
pathology and as a targeted therapeutic agent.  
  Accordingly, to further investigate the effects of disruption of Se metabolism in vivo, we 
conducted a series of experiments on male and female Sepp1 and Scly double knockout mice 
(DKOSe), which will be discussed in detail in subsequent chapters.  We hypothesize that the 
neurological deficits in the DKOSe are progressive in nature in both male and female mice and 
that the high Se diet and/or lack of high testosterone at puberty may be protective in the case of 
the female mice.  These studies have the potential to elucidate specific targets for further study in 
cases of fetal and childhood Se deficiency, and compensatory mechanisms that are distinct 
between males and females during development, as well as identify potential risk factors that 
may need to be considered in hormone replacement therapies. 
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Chapter 2: Physical Features Preceding Seizure 
Development in Male Sepp1 and Scly Double Knockout 
Mice 
 
Introduction 
 Selenium (Se) is an essential trace element linked to several biological functions in 
human health.  Through the incorporation of Se in the form of the amino acid selenocysteine 
(Sec), Se is thought to act mainly through selenoproteins.  Selenoproteins have been shown to 
play an important part in the defense against oxidative stress, which has implications for the 
development of disease states such as neurodegeneration.   
 Two proteins involved in Se metabolism are Selenoprotein P (Sepp1) and Selenocysteine 
lyase (Scly).  Sepp1 is involved in Se transport and lack of Sepp1 results in impairments in 
neurological function and male fertility (73; 78; 87; 88).  Scly catalyzes the breakdown of Sec, 
allowing Se to be recycled (95).  Scly is important in lipid and glucose metabolism (83; 97).   
Our lab developed and characterized a novel Scly and Sepp1 double knockout (DKOSe) 
mouse to investigate the in vivo effects of disrupted Se metabolism.  These mice are referred to 
hereafter as DKOSe, prefaced by M or F for male or female, respectively.  Se supplementation of 
dams and pups through their drinking water was required for pups to survive past weaning.  Even 
with Se supplementation in their drinking water, MDKOSe mice still developed neurological 
deterioration.  They exhibited decreased survival and severe neurological impairment, including 
loss of motor coordination, susceptibility to audiogenic seizures (AGS) and brain stem 
degeneration, with GABAergic system defects in the inferior colliculus (IC) (2). 
Due to the spontaneous development of seizures, MDKOSe may serve as a potential 
model for the study of epileptogenesis.  Therefore, statistical knowledge of the incidence of 
seizure development as well as physical features leading up to manifestation of seizures would 
be beneficial references for validating intervention therapies.  We hypothesize that seizure 
development in these mice is progressive in nature, therefore, there will be physical signs of 
deterioration preceding first seizure occurrence that can be monitored.  These include possible 
changes in weight, food and water intake, general behaviors e.g. approach response, posture, coat 
condition, and wobbly or abnormal gait.  Accordingly, we single-housed MDKOSe mice starting 
at five weeks of age, tested them weekly for motor coordination deterioration, and monitored 
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them for adverse physical signs of deterioration leading up to seizure development.  Then at ten 
weeks of age, they underwent testing for seizures in the Audio Open Field (AOF) assay and the 
lengths of their aura, ictal, and postictal stages were recorded.  
 
 
 
Materials and methods 
 All animal procedures and experimental protocols have been approved by the University 
of Hawai i’s Institutional Animal Care and Use Committee. 
  Animals: Male and female C57BL/6J (WTj), C57BL/6N (WTn), C57BL/6N on SeH2O 
(WTnSe) and DKOSe mice were generated from breeders in our colony as previously described 
(2). Because DKOSe mice require high selenium supplementation for survival, WTnSe and 
DKOSe dams were maintained on a 1 ppm Se diet consisting of standard chow containing 0.25 
ppm Se and water supplemented with 10 µM sodium selenite (~0.78 ppm Se) (hereafter SeH2O).  
Pups remained on the SeH2O water after weaning.  Animals were weighed and sacrificed and 
tissue collected thereafter at the same time of day (early evening, between 4:00-6:00 pm) to 
account for the 24 hour testosterone cycle.  Blood was collected via cardiac puncture, centrifuged 
at 13,000 x g for 10 minutes and serum taken and stored at minus 80˚C until analyzed.  Brains 
were either collected and weighed following perfusion with 4% paraformaldehyde (PFA) for 
histological analysis or dissected and snap frozen in liquid nitrogen and stored at minus 80˚C 
until use for protein, RNA, enzymatic activity or hormone analysis of specific brain regions.  
  Neuromotor and Behavioral tests: Mice were single housed 24 hours prior to behavioral 
testing except the group-housed mice used in preliminary studies. All tests were performed at the 
Hypothesis:  Seizure development in MDKOSe mice is progressive in nature, therefore, 
there will be physical signs of deterioration prior to first seizure occurrence that can be 
monitored. 
Aim:  Identify visual and behavioral characteristics leading up to the loss of motor 
coordination and onset of seizure activity in MDKOSe mice and obtain the average duration 
of the three seizure stages, aura, ictal and postictal. 
Significance:  MDKOSe mice may serve as a potential model for the study of ictogenesis.  
Data obtained can be used as a reference for evidence of any changes during future 
investigation of mechanistic pathways and for validating possible intervention therapies. 
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same time of day to account for circadian rhythm.  A select group of animals were assessed for 
motor coordination via Rotorod at weekly intervals from age 5 to 10 weeks.  All others subjected 
to behavioral testing were assessed beginning at 10 weeks of age.  After behavioral testing, mice 
were weighed, sacrificed and tissue collected as described above. Behavioral tests included the 
following:  
• Rotorod Assay for motor coordination (ataxia).  Mice were tested 4 times daily (two 
times in the morning and two times in the afternoon) for two consecutive days by being 
placed on a horizontal rod which increases rotation speed from 4 rpm to 40 rpm over a 5 
minute time period.  Latency to fall off the rod is averaged for the 8 trials.   
• Open Field Assay for locomotion.  Mice were tested by placement in an open field 
apparatus (50 x 50 cm) with 40 cm high opaque walls and allowed to explore for 5 
minutes. Animal movement was recorded by an overhead video camera and analyzed by 
video tracking software (VideoMot 2, TSE Systems).  Total distance traveled was 
recorded.  Average speed was calculated as total distance traveled divided by total time. 
• Audio Open Field (AOF) Assay for susceptibility to audiogenic seizures (AGS).  Mice 
were tested for AGS susceptibility as previously described (2).  Briefly, using the open 
field apparatus and video tracking software described above, mice were allowed to 
explore the open field for 2½ minutes, then were exposed to an 85 dB white noise played 
continuously through a loud speaker. Average speed during the pre-sound period of 2½ 
minutes (pre-sound) and in the initial 10 second period following the onset of white noise 
(post-sound) was calculated.  Trials were stopped if animal seized continuously for more 
than 15 seconds.  
• Seizure Trials.  This assay was conducted similar to AOF assay above except there was a 
5 minute acclimation period, followed by the 85 dB white noise being played for 15 
seconds only.  The total time of the aura duration (wild running), ictal duration (from the 
time mice fall over until they stop twitching) and postictal duration (time to regain 
upright on all four paws) were recorded. 
  Monitoring of food and water intake: A select group of mice were single housed starting 
at five weeks of age.  Their body weight, food consumption and water intake were assessed two 
times per week. When weight started to decline, assessment was increased to daily.  
  Body composition: Following sacrifice, total body weight, brain weight and weight of fat 
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depots of the inguinal (ingWAT) and gonadal (gWAT) white adipose tissue were collected and 
recorded. 
Statistical analysis: Statistical tests and sample number varied according to the 
experiment and are indicated in the text and/or figure legends.  Data were analyzed and plotted 
using GraphPad Prism version 5 Software.  All results are represented as mean ± SEM. 
Significance was determined by a p-value of <0.05.  
 
Results: C57BL/6 Genetic Background  
C57BL/6J (WTj) vs. C57BL/6N (WTn) mice 
 During the course of characterizing the DKOSe mice, we became aware of a possible 
complication due to genetic background.  DKOSe mice were developed using selected breeding 
techniques (2).  Briefly, SclyKO mice were bred with Sepp1 heterozygote mice.  Heterozygote 
(Het) offspring were then mated with SclyKO mice to produce SclyKO/Sepp1Het mice.  These 
were then crossed to produce DKOSe mice.  DKOSe mice are born with less than Mendelian 
ratios, indicating a possible embryotic selective process (2).  Since MDKOSe mice are infertile, 
FDKOSe are mated with SclyKO/Sepp1Het males to continue the colony.   
For breeding, our lab used both WTj and WTn mice.  In recent studies, it has been 
reported that the WTj mice have a mutation in their nicotinamide (NAD) nucleotide 
transhydrogenase gene (Nnt).  This gene encodes NAD(P) transhydrogenase, an inner 
mitochondrial membrane protein which catalyzes the reduction of NADP+ to NADPH.  NADPH 
is a cofactor in ATP synthesis as well as in antioxidant defense mechanisms.  WTj and WTn 
mice are reported to differ in metabolism and locomotor activity (98; 99; 100).  
The MDKOSe mice, which have deficits in locomotion and motor coordination, do not 
carry the Nnt mutation.  In the original study characterizing the MDKOSe mice (2), the control 
mice were the WTj mice on SeH2O supplementation, similar to the MDKOSe mice.  It is 
possible that some of the differences detected were influenced by the Nnt mutation in our 
controls.  In addition, in a study on testicular development using male Balb/c mice who were 
given a similar high selenium diet (1 ppm), it was found that the mice in this diet had a decrease 
in mRNA cFos/cjun regulation of redox status along with decreased sperm count and motility, 
similar to that of those on a Se deficient diet (101).  It is possible that the high selenium 
supplementation required for our controls may cause other differences in the WTj mice. 
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 Since both WTj and WTn mice were used in breeding, to determine if the absence of the 
Nnt gene had any significant effect on our previous data, we conducted the same behavioral tests 
that were used in the DKOSe characterization study (2) on WTj, WTn and WTn mice on SeH2O 
supplementation (WTnSe).  At ten weeks of age, the animals were sacrificed, brain and total 
body weight measured and the percentage of inguinal and gonadal white adipose tissue 
(ingWAT, gWAT) calculated relative to the total body weight. 
Sex appears to be a significant factor in motor coordination and locomotion with the 
females performing better than males in all three groups (Two-way ANOVA: Rotorod Sex 
p=0.009; Open Field Distance and Average Speed Sex p=0.0109).  SeH2O supplementation has a 
significant effect on motor coordination with MWTnSe performing significantly better then both 
MWTj and MWTn, and the FWTnSe trending toward better performance than FWTj and FWTn 
(Figure 2.1 A).  Both male and female distance traveled and average speed were similar between 
groups (Figure 2.1 B and C) and none showed susceptibility to AGS (Figure 2.2 A and B) 
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Figure 2.1: SeH2O Effect on Rotorod and Open Field Performance in WT Mice.  (A) Rotorod 
mean latency (mean±SEM) to fall and (B) Open field distance traveled and (C) Average speed 
over a 5 minute period of male and female WTj, MWTn and MWTnSe mice (Rotorod: Two-
way ANOVA Interaction NS, Genotype F(2,44)=8.43, p=0.0008; Sex F(1,44)=7.47,  p=0.009; 
Open Field Distance: Two-way ANOVA Interaction NS, Genotype NS, Sex F(1,37)=7.18, 
p=0.0109; Open Field Average Speed: Two-way ANOVA Interaction NS, Genotype NS, Sex 
F(1,37)=7.17, p=0.0109; Bonferroni Post Test **p<0.01 (MWTj n=6-7, FWTj n=5-6, MWTn 
n=3-9; FWTn=5-8; MWTnSe and FWTnSe n=11). 
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When looking at specific body weight composition, sex and genotype were significant 
factors contributing to differences in total body weight (Two-way ANOVA Sex p<0.0001, 
Genotype p=0.022), brain weight (Two-way ANOVA Sex p=0.0141, Genotype p<0.0001) and 
gWAT% (Two-way ANOVA Sex p=0.0002, Genotype p=0.0013).  Bonferroni post hoc test 
revealed MWTn obtained significantly higher total body weight than both MWTj and MWTnSe.  
This seems to be reversed when looking at ingWAT% and gWAT%.  MWTn had decreased 
ingWAT% and gWAT% compared to both MWTj and MWTnSe, reaching significant 
differences in gWAT% (Figure 2.3).  For brain weight, only MWTj had significantly different 
brain weight compared to MWTn and MWTnSe in the males, but in females all three groups 
were significantly different from each other (Figure 2.3). 
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Figure 2.2: SeH2O Effect on Audiogenic Seizure Susceptibility in WT Mice.  Speed prior 
to 85 dB white noise sounding and 10 seconds immediately after start of 85 dB white noise 
of (A) male and (B) female WTj, WTn, and WTnSe mice (Two-way ANOVA: (A) 
Interaction, Genotype and Pre verses Postsound NS; (B) Interaction and Pre verses 
Postsound NJ, Genotype F(2,40)=5.79, p=0.0062; Bonferroni posttests **p<0.01; MWTj 
and FWTJ n=6; MWTn n=5; FWTn n=6; MWTnSe and FWTnSe n=11). 
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Results: Seizure Stage Characterization and Physical Signs for Seizure Development 
Seizure Susceptibility 
 As previously stated above, MDKOSe mice exhibit susceptibility to audiogenic seizures 
(AGS) starting around 8 weeks of age with few surviving past 14 weeks of age (2). The physical 
condition of the animals leading up to seizure and the length and duration of these seizures has 
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Figure 2.3: SeH2O Effect on Body Composition in WT Mice.  (A) Total body weight, (B) 
brain weight, and (C) percentage of ingWAT and (D) gWAT of male and female WTj, WTn, 
and WTnSe mice. (Two-way ANOVA, Total Body Weight: interaction p= 0.0173 
F(2,49)=4.41, Genotype p=0.0222, F(2,49)=4.12; Sex p<0.0001, F(1,49)=251.50; Brain Weight: 
interaction p=0.1978, F(2,48)=1.68, Genotype p<0.0001, F(2,48)=0.0141, Sex p=0.0141, 
F(1,48)=6.49; % ingWAT: NS; %gWAT: interaction p=0.1318, F(2,46)=2.12, Genotype 
p=0.0013, F(2,46)=7.67, Sex p=0.0002, F(1,46)=16.47; Bonferroni Post Hoc test: 
*p<0.05,**p<0.01, ***p<0.001) (MWTj and FWTj n=4-7, MWTn and FWTn n=4-8, 
MWTnSe and FWTnSe n= 14-15). 
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yet to be characterized.  Identification of reliable visual and behavioral characteristics leading up 
to seizure activity in the MDKOSe mice and the average duration of their aura, ictal and postictal 
stages would be important parameters for identifying potential effects of any future therapeutic 
interventions. 
Previous studies from our laboratory reported 25-40% survival at 12-14 weeks (2; 102).  
Analysis of two additional MDKOSe groups showed that at 8 weeks of age (Group A) about 
33% of MDKOSe start to show susceptibility to seizures and at 10 weeks of age (Group B), 40% 
required to be euthanized prior to behavioral testing with an additional 33% developing seizure 
susceptibility by 10 weeks (Table 2.1).  Therefore, based on these data, we estimated that about 
33% to 40% of the male mice will show neurological problems with susceptibility to seizures 
around 8 weeks of age and additional 33% by 12 weeks, for an approximate total in the mid 60 to 
mid 70 percent range. 
 
Table 2.1: MDKOSe Mice Statistics. (Abbreviation: P = Postnatal Day) 
MDKOSe # of 
animals 
Age Range Respond to Seizure 
Test 
(Audio Open Field) 
Required to be 
Euthanized prior to 
behavioral testing 
Group A 26 P49-54 (7 to 8 weeks) 33% 0% 
Group B 21 P64-86 (9 to 12 weeks) 33% 40% 
 
To further characterize the physical signs of seizure development, a select group of 
MDKOSe mice were single housed and monitored for behavioral deterioration.  They were 
assessed on the Rotorod weekly starting at 5 weeks of age.  Measurements were made for weight 
change, food and water intake, approach response, posture, coat condition, and wobbly or 
abnormal gait.  At 10 weeks of age, mice underwent testing for seizures in the Audio Open Field 
(AOF) test, as previously described in Byrns et al., 2014 (2).  The aura, ictal, and postictal 
lengths were recorded. The mice were grouped into those that had evidence of seizures prior to 
AOF Test (Seizure Prior AOF) and those in which had no evidence of seizures prior to the test 
but had a seizure when tested in the AOF test (1st Seizure During AOF). 
 
Seizure Incident and Physical Signs 
The percentage of seizure occurrence was similar to our previous results.  Out of nine 
mice, one died spontaneously at eight weeks, 33% had evidence of seizures by nine weeks of age 
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and an additional 33% by ten weeks of age, making a total of 77%.  For those that were observed 
past this age, all eventually developed AGS (n=2). Surprisingly, the average period of weight 
loss was the same regardless of age of seizure onset (Table 2.2).  An additional group was 
monitored for food and water intake during their weight loss period and weight loss appears to be 
accompanied by an average decrease of food intake (14%) and water intake (9%) (Figure 2.4) 
indicating that weight loss may be used as a sign of disease progression to a deteriorating.  
 
Table 2.2: MDKOSe Weight Loss and Seizure Onset.  Average age of weight loss onset, weight 
loss period, period between weight loss start and seizure onset and percentage of animals of 
MDKOSe (n=9, Abbreviations: P = Postnatal day, d = days). 
MDKOSe Ave Age 
Weight 
loss Start 
(P) 
Ave Period 
of Weight 
Loss  
(d) 
Ave Period 
between 
beginning of 
Weight Loss and 
Observance of 
1st Seizure (d) 
Ave Age 
Seizure 
Onset (P) 
% of 
Animals 
Seizure Prior to AOF  57 8 6 63 33% 
1st Seizure during AOF  61 8 9 70 33% 
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Figure 2.4: MDKOSe weight loss, food, and water intake.  Percentage of weight change (A), 
food intake (B), and water intake (C) of MDKOSe mice which were losing weight (n=3).  
Weight change average was -9.0545%/day (slope of graph); Food intake slope -0.4845 or -
14%/day decrease in food intake; Water intake slope -0.3169 or -9%/day decrease in water 
intake.   
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Motor Function 
Weekly Rotorod testing revealed that MDKOSe mice have significant decreases in motor 
coordination compared to their wild type counterparts starting at six weeks of age (Figure 2.5).  
Wobbly gait was the first visual sign evident prior to the beginning of weight loss, occurring 
over a 2 to 5 day period (average of 4 days, data not shown).  Weight loss began an average of 6 
to 9 days prior to seizure development, and was more rapid in those mice that develop seizures at 
early ages (Table 2.2).   
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Figure 2.5: MDKOSe Weekly Rotorod Performance.   
Mean latency to fall of male DKOSe and WTnSe mice 
from five to ten weeks of age (Two-way ANOVA: 
Interaction F(5,60)=3.10, p=0.0148; Genotype 
F(1,60)=100.59, p<0.0001; Week NS; Bonferroni post-test   
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Seizure Stages 
When the average aura, ictal and postictal lengths were compared, the differences 
between the two groups were mainly seen in the postictal state.  Aura periods were of similar 
length with the ictal period being one and a half times longer in the Seizure Prior AOF group.  In 
the postictal stage the average time it took for animals to start to move after the end of the ictal 
stage (1st Try) was three times longer in the Seizure Prior AOF group, and the total time to regain 
all 4 paws (postictal) was seventeen times longer (Figure 2.6), indicating that seizure recovery 
times are lengthened as the condition of the animal deteriorates. 
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Figure 2.6: MDKOSe Duration of Seizure Stages.  
Average lengths of aura, ictal, 1st try, and postictal of 
MDKOSe mice that had seizures prior to and 1st seizure 
during the AOF test (Two-way ANOVA Group F(1,16) 
=31.34, p<0.0001; Stage F(3,16) =39.43, p<0.0001; 
Bonferroni posttest ***p<0.001, n=3) 
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Discussion: 
Genetic background of DKOSe Mice 
  Under the parameters tested, the gWAT% in males and brain weight in females appear to 
be the only significant differences between WTj and WTn mice.  The main effect of SeH2O 
supplementation appears to be on motor coordination, as indicated by results of the Rotorod test 
and the percentage of male gWAT.  Though the increased Rotorod performance may appear to 
be a benefit, the increase in percentage of gWAT to that comparable to WTj may indicate a 
change in a metabolic process.  The Nnt mutation has been known to affect insulin and glucose 
metabolism.  WTj mice have been used as a model for diet-induced diabetes, with males being 
less glucose tolerant than females (103). Transgenic rescue of Nnt was shown to rescue insulin 
and glucose tolerance and β-cell function (100).  However, on a low-fat diet, WTj have a slight 
impairment in glucose stimulated insulin secretion (104). The gWAT of WTj has been said to be 
limited in its storage of fat deposits and reaching this limit is a precursor to the development of 
metabolic syndrome disorders in MWTj mice (105).  The significantly higher percentage of 
gWAT in WTnSe compared to WTn mice may indicate that SeH2O supplementation may be 
having a metabolic effect in these mice.  Further observations over a longer time period along 
with the application of metabolic tests may be necessary to investigate this further. 
The fact that no MDKOSe mice are born with the WTj mutation indicates that, with 
reduced Se metabolism, a functional Nnt gene may be necessary for MDKOSe embryonic 
survival.  The Nnt gene encodes for NAD(P) transhydrogenase, an inner mitochondrial 
membrane protein which uses energy from the proton gradient to catalyze the reduction of 
NADP+ to NADPH.  Loss of NAD(P) transhydrogenase activity leads to a decrease in energy 
production and the GSH/GSSG ratio along with increased sensitivity to oxidative stress (106).  It 
has also been reported that the enzyme may have a role in the modification of another 
antioxidant, the mitochondrial superoxide dismutase (mtSOD).  The absence of both NAD(P) 
transhydrogenase and mtSOD leads to fetal dilated cardiomyopathy and embryonic death in WTj 
mice (106).   
Se is an important component of proteins that have antioxidant activities, e.g. Txnrd.  
Deletion of either Txnrd1 or Txnrd2, ubiquitously expressed selenoproteins located in the 
cytosol and mitochondria, respectively, is embryonic lethal.  Txnrd 2 deletion lethality is due to a 
disruption in cardiac development (79).  It is possible that similar to mtSOD deletion in WTj 
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mice, the ability of the body to maintain redox balance is severely compromised under the extra 
metabolic strain of Nnt loss in combination with the reduced Se availability for selenoprotein 
synthesis leading to embryonic lethality.  Studies on selenoproteins and their effects on 
embryonic development would be needed to investigate this possibility. 
 
Physical features preceding seizure development in MDKOSe mice 
MDKOSe spontaneously develop seizures starting around 8 weeks of age.  Knowledge of 
the physical features leading up to manifestation of seizures may serve as a reference for 
validating intervention therapies.  Accordingly, we carried out studies to further characterize 
objective signs of seizure development.   
Using our previous data, we estimated that approximately 75% of MDKOSe mice that 
would have susceptibility to seizures between 8 and 12 weeks of age.  As predicted, the 
percentage of mice that developed seizures in this study fell close to this estimation, being 77%.  
Loss of body weight appears to be a reliable indicator of when seizures would start to occur, 
commencing approximately a week before seizure development.  This approximation was 
limited to our ability to observe 1st seizure occurrence through daily checks by animal care staff 
and additional observations made by the researcher at least 3 times a week.  This leaves a 
potential 24 hour gap in time in which the animals are not observed.   A 24 hour monitoring 
system would eliminate this and is recommended for monitoring how often seizures occur once 
they begin.   
Weight loss was accompanied by a decrease in food and SeH2O intake which still leaves 
the question as to whether this is a compounding factor.  Decreased food and SeH2O intake leads 
to further decrease of Se intake and may thereby accelerate seizure progression.  It is possible 
that forced food and SeH2O intake could prevent weight loss but not prevent seizure 
development as, in the animals studied beyond 10 weeks of age, all mice eventually developed 
seizures.  This suggests that seizure development is connected to an aging process in which each 
mouse is affected differently e.g. some by 8 weeks, others by 10 weeks, and still others much 
older. 
Se deficiency has the potential to cause epigenetic changes in metabolites (35).  
Alterations in the levels of different metabolites involved in one-carbon metabolism have 
downstream effects on methylation and hormone biosynthesis which can cause a variety of 
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developmental effects (35; 36; 37; 38; 39).  Investigations into the subtle differences that delay 
seizure onset in one mouse verses another may help reveal key components which determine 
seizure development, and reveal potential targets for therapeutic intervention. 
 
Conclusion 
In this study, 77% of MDKOSe developed seizure characteristics by 10 weeks of age.  
Decreased motor coordination started around 6 weeks of age along with wobbly or abnormal gait 
which preceded weight loss.  Seizure development occurred within a week after weight loss 
commencement, which was accompanied by a decrease in food and water intake.  
Based on these results, we estimate that 70-80% of MDKOSe mice will develop the 
seizure phenotype.  This will start with loss of motor coordination along with a wobbly or 
abnormal gait.  Weight loss will begin prior to first seizure occurrence with postictal duration 
increasing as the mice continue to have seizures. Using the excessive weight loss criteria, about 
40% of the animals will require euthanasia prior to 10 weeks of age.  
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Chapter 3: Effects of High Se Supplementation on 
Neuromotor Deficit in Female Sepp1 and Scly Double 
Knockout Mice 
 
Introduction 
Se metabolism has been shown to differ between the sexes, with females being able to 
retain Se better in all tissues except the brain and reproductive organs (76; 107).  Single gene 
knockout of Sepp1 or Scly resulted in detrimental neurological or metabolic phenotypes that 
were more pronounced in males. Thus, studies of these mouse models focused on males, with 
females only assessed in preliminary initial studies. 
In previous studies published by our laboratory on Sepp1 and Scly Double Knockout 
(DKOSe) mice, we reported that when both Sepp1 and Scly genes were disrupted, male DKOSe 
(MDKOSe) mice exhibited decreased survival and severe neurological impairment, including 
loss of motor coordination, susceptibility to audiogenic seizures (AGS) and degeneration in brain 
nuclei and tracts involved in auditory and motor pathways, with GABAergic system defects in 
the inferior colliculus (IC) (2).  Female DKOSe (FDKOSe) mice exhibit a milder phenotype so 
they were not examined in detail at the time of MDKOSe study. 
Although the FDKOSe mouse phenotype does not appear to be as severe as that of the 
MDKOSe, further characterization revealed FDKOSe mice do display significantly less motor 
coordination than their wild type counterparts, C57BL/6N (FWTnSe), as tested by Rotorod assay 
at 10 weeks of age (Figure 3.1 A).  Total body weight of FDKOSe was also significantly greater 
than FWTnSe (Figure 3.1 B).  These results suggest a milder neurological phenotype with a 
metabolic component in FDKOSe mice.  Therefore, we hypothesize that, like the MDKOSe 
mice, FDKOSe mice neuromotor deficit is progressive in nature and that the high Se 
supplementation may be protective in the female mice.  To further investigate the FDKOSe 
neuromotor and/or metabolic phenotype, we assessed their neuromotor function by performance 
on a Rotorod at weekly intervals from ages 5 to 10 weeks and measured their body fat 
composition and fasting insulin levels at 10 weeks of age.  For a subgroup of FDKOSe mice, we 
removed the high Se supplementation at different ages and conducted the same behavioral test 
previously used to characterize the MDKOSe mice.   
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Materials and methods 
  Animals: Mice were generated, maintained, and samples collected as previously 
described in Chapter 2.   
  Neuromotor and Behavioral tests: All analyses were conducted as described in Chapter 
2. 
  Body composition: Tissue weights were collected and recorded as described in Chapter 2. 
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Figure 3.1: Rotorod Performance and Body Weight on Male and Female WTnSe and 
DKOSe Mice. (A) Mean latency to fall and (B) Total body weight of male and female 
WTnSe and DKOSe mice at 10 weeks of age (Two-way ANOVA: Rotorod p<0.0001, 
Genotype F(1,40)=53.63 p<0.0001, Sex F(1,40)=7.05 p=0.0113, n=11 all groups; Two-way 
ANOVA: Body Weight Genotype F(1,16)=12.40 p=0.0028, Sex F(1,16)=33.87 p<0.0001, n=5 
all groups; Bonferroni *p<0.05, ***p<0.001). 
 
Hypothesis:  Similar to the MDKOSe mice, FDKOSe mice neuromotor deficit is 
progressive in nature and the high Se supplementation may be protective in the females. 
Aim:  Investigate the possible neuromotor deficit and metabolic phenotype in FDKOSe and 
determine what role the high Se supplementation may play on the female phenotype. 
Significance:  Reveal possible compensatory mechanisms that are distinct between males 
and females during development. 
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  Fasting serum insulin levels: Animals were fasted for 5 hours then sacrificed and blood 
was collected at the same time of day, between 5:30-6:30 pm.  It was then centrifuged at 13,000 
x g for 10 minutes and the serum collected and stored at minus 80˚C until assayed for insulin 
levels. Insulin levels were measured using ALPCO mouse ultrasensitive insulin ELISA kit 
(cat#80-INSMSU-E01) pursuant to the manufactures instructions. 
  Histology and immunohistochemistry:   Tissue was collected and processed as previously 
described (102).  Briefly, mice were deeply anesthetized using 1.2% Avertin and perfused 
intracardially with 0.1 M sodium phosphate buffer (PB) followed by 4% PFA in PB. Brains were 
removed, stored in 4% PFA for 24 hours, then immersed sequentially in 10%, 20%, and 30% 
sucrose in PB (24 hours each solution).  Brains were cut into 40 µm coronal sections. To assay 
for reactive gliosis, sections were incubated with primary antibody-GFAP (Dako #Z0334).  
GFAP was visualized using diaminobenzidine tetrahydrochloride (DAB) immunohistochemistry, 
sections were treated with 0.3% H2O2, blocked, and incubated in primary antibody overnight at 
4°C.  The sections were then probed with the appropriate biotinylated secondary antibody 
followed by incubation in avidin-biotin-peroxidase complex (Vectastain Elite ABC Kit, Vector 
Labs # PK6100) and visualized by peroxidase detection using DAB HRP Peroxidase Substrate 
Kit (Vector Labs # SK4100).  Sections were mounted, dehydrated with graded solutions of 
ethanol followed by xylene, and cover slipped.  
Silver staining: Silver staining was performed using the FD Neurosilver Kit II (FD 
Neurotechnologies # PK301) according to the manufacturer’s instructions. 
Protein extraction and immunoblotting: Mice were euthanized by CO2 inhalation and 
brains were quickly removed.  Brains were cut in half along the longitudinal fissure, with one 
hemisphere being snap-frozen in liquid nitrogen for use as a whole-brain sample.  The remaining 
hemisphere was dissected and the cerebellum, brainstem, and hippocampus snap-frozen in liquid 
nitrogen for later analysis.  Frozen tissues were lysed by sonication in CelLytic MT Cell Lysis 
Reagent (Sigma-Aldrich # C3228) containing protease inhibitors (Calbiochem # 539134) and 
centrifuged at 14,000 x g for 10 minutes at 4°C. Supernatants were collected, and the protein 
concentrations were measured using Nanodrop NP-1000 spectrophotometer.  For Western 
blotting, 40 µg samples of total protein were separated on 4%–20% SDS-PAGE gradient gels 
(Bio-Rad # 567-1094), transferred to Immobilon-FL PVDF membranes (VWR, 28298-022), and 
probed for 2 hours at room temperature with specific primary antibodies.  Membranes were then 
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incubated in the dark with secondary antibodies coupled to infrared fluorophores (LI-COR 
Biosciences).  Blots were imaged and analyzed using an Odyssey infrared imager (LI-COR 
Biosciences) together with Image Studio Version 4.0.  Relative protein levels were determined 
by dividing the optical density of the band representing the protein of interest by that of loading 
controls, α-tubulin or β-actin.  For determining the Gpx3 levels in the serum, Ponseau S in 1% 
(v/v) acetic acid was used to visualize protein bands for normalization.   Blots were then washed 
5 minutes in 5% acetic acid (v/v) followed by two 5 minute washes in dH2O, then blocked and 
probed with primary and secondary antibodies as stated above.  To simplify for comparative 
purposes, the mean normalized optical density for each protein was reported as a ratio to female 
wildtype (FWT) normalization. 
Antibodies: The primary antibodies used for immunohistochemistry were as follows: 
rabbit anti-GFAP (1:2000; DAKO Z0334).  The primary antibodies used for Western blotting 
were as follows: mouse anti-glutathione peroxidase 3 (1:500; LabFrontier LF-MA0114), rabbit 
anti-type 3 deiodinase (1:1000; Novus Biologicals NBP1-05767B), and mouse anti-α-tubulin 
(1:5000; Novus Biologicals NB100-690) 
Gpx activity assay: Soluble proteins were extracted as described above.  Samples were 
diluted to 4 μg/μl in Gpx buffer consisting of 50 mM phosphate buffer + 5mM EDTA, pH=7.4.  
Then 25 μl of sample were loaded into a 96 well plate and incubated at 37˚C for 3 minutes in 45 
μl of master mix: 12.5 μl of 30 mM glutathione (Sigma CAS 70-18-8), 12.5 μl of 30 μg/ml 
glutathione reductase (Sigma 9001-48-3), and 20 μl of 1mM NADPH (Sigma 2646-71-1)).  Five 
μl of 6 mM tert-tutyl hydroperoxide solution was then added to each sample and the plate was 
read by a Spectramax M3 plate reader (Molecular Devices) at 340 nm for 10 minutes.  Using 
Softmax Pro 6.2.1 software, the Gpx activity was measured values determined as the reduction 
rate of tert-butyl hydroperoxide catalyzed by the samples upon the oxidation of glutathione and 
reduced NADPH.  A unit of activity was defined as the consumption of 1 μmol of NADPH per 
minute, calculated from the equation (Vmax x Vt/Vs)/(0.0062 x D), using 0.0062 μM-1 cm-1 as 
the extinction coefficient for NADPH at 340 nm. 
Quantification: The optical density of GFAP immune reactivity and silver staining in the 
IC and XSCP was quantified at the same coronal levels, -5.02 and -4.48 mm respectively.  
Brightfield images (5 x objective) were captured with a digital camera mounted on a Zeiss 
microscope (Axioskop2), imported into ImageJ analysis software, and converted to black-and-
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white images. Contours were drawn around the area of interest and the adjacent area (as 
background control).  Mean optical density was determined as the difference between the area of 
interest and the background control contour.   
Statistical analysis: All were conducted as described in Chapter 2. 
 
Results 
Comparison of physical features and motor performance for male and female DKOSe mice on Se 
supplementation 
Weekly Rotorod averages showed that FDKOSe mice do indeed exhibit a milder 
neurological deficit, with “latency to fall” times that were between those of FWTnSe and 
MDKOSe mice (Figure 3.2).  FDKOSe mice exhibit a decrease in motor coordination starting at 
7 weeks of age compared to their FWTnSe counterparts.  In body composition, there were no 
significant differences in brain weight (Figure 3.3 B).  The FDKOSe mice had significantly 
higher total body weight (Figure 3.3 A) and percentage of inguinal (%ingWAT) and gonadal 
(%gWAT) white adipose tissue (Figure 3.3 C & D) when compared to their FWTnSe 
counterparts, but their fasting insulin levels were not significantly different when compared to 
controls (Figure 3.4).  These results indicate that even with SeH2O supplementation, FDKOSe 
mice develop a neurological deficit. 
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Figure 3.2: Weekly Rotorod Performance of Male and Female WTnSe 
and DKOSe Mice.  Mean latency to fall from 5 to 10 weeks of age of 
male and female WTnSe and DKOSe (Two-way ANOVA: Interaction 
F(15,120)=1.85 p=0.0355, Genotype F(3,120)=42.17 p<0.0001, Week 
F(5,120)=2.74 p=0.5071; Bonferroni: MWTnSe v MDKOSe 6wk-10wk 
p<0.01, FWTnSe v MDKOSe 6wk-10wk p<0.01; MWTnSe v FDKOSe 
6, 9, 10 wk p<0.05; FWTnSe v FDKOSe 6, 9 wk<0.05; FDKOSe v 
MDKOSe 7wk <0.001; n=6 all groups) 
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Figure 3.3: Body Composition in Male and Female WTnSe and DKOSe Mice.  Body (A), 
brain (B) and percentage of ingWAT (C) and gWAT (D) of male and female WTnSe and 
DKOSe mice at 10 weeks of age (Two-way ANOVA: Body weight, genotype F(1,52)=60.68 
p=<0.0001, Sex F(1,52)=75.15 p<0.0001; Brain NS; IngWAT Interaction F(1,52)=7.54 p=0.0083, 
Genotype F(1,52)=31.51 p<0.0001, Sex F(1,52)=12.64 p=0.0008; and gWAT Interaction 
F(1,52)=18.64 p<0.0001, Genotype F(1,52)=47.51 p<0.0001 Bonferroni ***p<0.001, n=14 all 
groups). 
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Impact of timing of SeH2O removal on motor performance for FDKOSe mice 
A Se deficient diet appears to aggravate the phenotype in males of both the Sepp1KO and 
SclyKO.  To date, the FDKOSe tested were on a high Se supplemented diet through their 
drinking water as described in the previous chapter (SeH2O).  In order to determine if their motor 
developmental was related to Se supplementation, we removed the SeH2O supplementation from 
FDKOSe at different ages, postnatal day (P) 22, 37 or 42, and tested for motor coordination and 
susceptibility to seizure development. 
Rotorod performance of FDKOSe-NoSe P42, P37 or P22 groups that survived to P70 
showed a trend of decreasing latency to fall times when compared to FDKOSe mice maintained 
on SeH2O through P70 (Figure 3.5).  Surprisingly, it was found that the performance of the 
FDKO-NoSeP22 that survived to P70 did not change from P34 to P83.  The mice that did poorly 
on P34 did equally poorly on P83 (data not shown) indicating that motor deficits were acquired 
at an early time point prior to P70. 
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Figure 3.4: Five Hour Fasting Serum Insulin 
Levels in Male and Female WTnSe and DKOSe 
Mice.  Serum insulin levels of male and female 
DKOSe and WTnSe mice. (Two-way ANOVA 
Sex F(1,35)=19.15 p<0.0001; Bonferroni NS; 
WTnSe n=3, DKOSe n=4; triplicate) 
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Further characterization of FDKOSe mice maintained on SeH2O through P22, P37 and 
P70 revealed that removal of SeH2O at P22 produced a more detrimental outcome as compared 
to Se removal at the later postnatal dates, resulting in motor performance approaching what we 
originally observed in MDKOSe mice maintained on SeH2O throughout.  In the FDKOSe-
NoSeP22 mice, 83% exhibited motor deficit and/or susceptibility to seizures by ten weeks of age 
(Table 3.1). They had significantly reduced latency to fall times compared to all other groups 
tested (Figure 3.6 A).  Assessment of locomotion and exploratory behavior in the open field 
assay showed FDKOSe-NoSeP22 mice traveled significantly less (Figure 3.6 B) over a 5 minute 
period of time and at significantly slower speeds (Figure 3.6 C).  In the audiogenic seizure assay, 
FDKOSe-NoSeP22 mice exhibited wild running in response to an 85 dB white noise (Figure 3.6 
D).   
When we looked at body composition, FDKOSe-NoSeP22 mice had significantly lower 
total body weight compared to FDKOSe mice with ingWAT% trending lower than FDKOSe.  
Their gWAT% that was intermediate between FDKOSe and FWTnSe mice with significantly 
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Figure 3.5: Effect of SeH2O Withdrawal Age on 
Rotorod Performance in FDKOSe Mice.  Latency to fall 
of FDKOSe, FDKOSe-NoSeP42, P37 and P22 mice at 
10 weeks of age (n=4 all groups except P37 n=3) 
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higher gWAT% compared to FWTnSe yet significantly lower gWAT% than the FDKOSe mice 
(Figure 3.7).  Removal of SeH2O at P37 resulted in FDKOSe-NoSeP37 mice having significantly 
lower gWAT% compared to FDKOSe mice but no differences in the other tissue weighed 
(Figure 3.7).   
 
Table 3.1: FDKOSe Motor Deficit and/or Seizures Development Percentages by SeH2O 
Removal Age. 
Age to which SeH2O was 
continued 
% of mice that exhibited motor 
deficits and/or seizures by P70 
% of mice required to be 
euthanized prior to P70 
P22 83% 28% 
P37 29% 0% 
P70 0% 0% 
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Figure 3.6: Effect of SeH2O Withdrawal Age on Rotorod, Open Field and Audio Open Field in 
FDKOSe Mice.  Mean latency to fall (A), distance traveled (B) and average speed (C) in open 
field. Average speed 2½ minutes prior (PreSpeed) and 10 seconds after (PostSpeed) 85 dB 
white noise played (D) of female WTnSe, DKOSe, DKOSe-NoSeP37 and DKOSe-NoSeP22 
mice at 10 weeks of age (One-way ANOVA: Rotorod p<0.0001, FWTnSe and FDKOSe n=14, 
P37 n=7 and P22 n=11; One-way ANOVA: Open Field Distance p=0.0084, Ave. Speed 
p=0.0084, FWTnSe and FDKOSe n=12, P37 n=7, P22 n=10; Audio Open Field NS n=11 all 
groups except FDKOSe-NoSeP37 n=4; Tukey’s Multiple Comparison Test *p<0.05, 
**p<0.005, ***p<0.0005). 
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Assessment of neuroinflammation and neurodegeneration in DKOSe mice 
As the FDKOSe-NoSeP22 neuromotor performance was decreased similar to what has 
been observed in the MDKOSe in the past, we assessed neurodegeneration in same areas of the 
brain found to be affected in the MDKOSe, the inferior colliculus (IC) and decussation of the 
superior cerebellar peduncle (XSCP), along with brain Gpx activity.  FDKOSe-NoSeP22 mice 
exhibited significantly higher levels of GFAP average optical density in the IC and XSCP 
compared to FWTnSe, FDKOSe and FDKOSe-NoSeP37 (Figure 3.8), indicating substantial 
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Figure 3.7: Effect of SeH2O Withdrawal Age on Body Composition of FDKOSe Mice.  Body 
(A), brain (B) and percentage of ingWAT (C) and gWAT (D) of female WTnSe, DKOSe, 
DKOSe-NoSeP37 and DKOSe-NoSeP22 at 10 weeks of age (One-way ANOVA Total Body 
p=0.0002, Brain NS, ingWAT% p=0.0005, gWAT% p<0.0001; **p<0.005, ***p<0.0005; 
n=13 all groups except P37 n=4). 
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astrocyte reactivity.  Silver staining, a stain used to detect degenerating neuronal somata, axons 
and terminals which become argyrophilic as they deteriorate, showed significant 
neurodegeneration in the axons of the motor tracts in the XSCP of FDKOSe-NoSeP22 mice 
(Figure 3.9).  When we examined Gpx activity levels there were no significant differences 
between FDKOSe and FDKOSe-NoSeP22 mice.  Both had significantly decreased levels in the 
whole brain compared to FWTnSe mice.  In the brain stem there was a trend of decreased levels 
with FDKOSe-NoSeP22 having the lowest levels (Figure 3.10).  
 
 
 
Figure 3.8: Effect of SeH2O Withdrawal Age on Glial Fibrillary Acidic Protein (GFAP) 
Immunoreactivity in FDKOSe Mice.  A. Representative images of IC and XSCP of FWTnSe, 
FDKOSe, FDKOSe-NoSeP37 and FDKOSe-NoSeP22 GFAP mice at 10 weeks of age with 
quantification of average optical density, IC (B) and XSCP (C). (One-way ANOVA IC 
p=0.0003, XSCP p=0.0151; Tukey’s *p<0.5, **p<0.005, ***p<0.0005; n=3 all groups). 
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Figure 3.9: Effect of SeH2O Withdrawal Age on Silver Staining in FDKOSe Mice.  A. 
Representative images of silver staining in IC and XSCP of FWTnSe, FDKOSe, FDKOSe-
NoSeP37 and FDKOSe-NoSeP22 mice at 10 weeks of age with quantification of average 
optical density, IC (B) and XSCP (C) (One-way ANOVA IC NS, XSCP p=0.0187; Tukey’s 
*p<0.5; n=3 all groups). 
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Impact of the DKOSe genotype on thyroid metabolism 
 The FDKOSe neurological phenotype appears to be dependent on SeH2O 
supplementation through a specific developmental time point, P37.  Selenoproteins play a role in 
bodily processes such as thyroid hormone (TH) metabolism.  TH affects the metabolic activities 
of most tissues and is important in growth and development.  Selenoproteins are also important 
in oxidative stress defense, which has implications in the development of disease states such as 
neurodegeneration.  We investigated two selenoproteins that might give insight into which of 
these processes are influenced, brain stem type 3 deiodinase (Dio3) and serum glutathione 
peroxidase 3 (Gpx3).   
Dio3, a critical selenoenzyme in thyroid hormone metabolism, was present in the brain 
stems of 8 week old MDKOSe mice at almost double the level found in FDKOSe, and was also 
elevated compared to WT male and female mice (Figure 3.11 A). In FDKOSe mice, Gpx3 was 
elevated approximately 25% more in the serum compared to MDKOSe mice, and it was 
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Figure 3.10: Effects of SeH2O Withdrawal Age 
on Glutathione Peroxidase (Gpx) Activity 
Levels in FDKOSe Mice. Gpx Activity in the 
whole brain and brain stem of FWTnSe, 
FDKOSe and FDKOSe-NoSeP22 mice at 10 
weeks of age. (One-way ANOVA WB 
p<0.0001; BS NS p=0.0820; Tukey’s Post Hoc 
Test ****p<0.0005, n=3 to 4 in triplicates) 
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significantly greater compared to wild type females (Figure 3.11 B).  These data indicate that 
there may be a possible TH effect in these mice but as these findings are preliminary further 
investigations are needed to determine this.  
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Figure 3.11: Serum Gpx3 and Brain Stem Dio3 Levels in Male and Female DKOSe mice.  
Mean normalized protein levels relative to FWT in brain stem (A) and serum (B) of male and 
female WT and DKOSe mice at 10 weeks of age. (Two-way ANOVA: Dio3 NS; Gpx3, 
Genotype F(1,12) =8.64 p=0.0124, Sex F(1,12) =3.59 p=0.0826, Bonferroni post-test *p<0.05, 
n=4 all groups). 
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Discussion 
In the previous study characterizing DKOSe mice, the severe phenotype of MDKOSe 
was not observed in FDKOSe (2). Herein, we confirm that FDKOSe mice exhibit a milder 
neurological phenotype.  FDKOSe mice have decreased Rotorod performance starting at seven 
weeks of age, a week later than MDKOSe mice.  A significant reduction in performance 
compared to FWTnSe was observed when they reached nine weeks of age indicating that, though 
milder, this condition was progressive.   
SeH2O supplementation until at least P37 appears to be critical in preventing the more 
severe consequences observed in MDKOSe from occurring in FDKOSe mice.  With SeH2O 
removal at weaning (P22), FDKOSe mice developed a phenotype similar to that seen in 
MDKOSe mice.  They had significant decreases in motor coordination and locomotion, along 
with increased susceptibility to seizure development.  Neuroinflammation and neurodegeneration 
were evident in the same areas of the brain, IC and XSCP, as previously observed in MDKOSe 
mice, indicating the possibility that the same developmental factors and/or mechanistic pathways 
are disrupted in both males and females. 
MDKOSe mice develop increased susceptibility to audiogenic seizures (AGS) with 
GABAergic system defects including decreased GAD67 and PV+IN density in the IC (2).  Other 
mouse models of AGS have shown that GABAergic system defects during a critical postnatal 
development period of P12-22 is a factor in rodent susceptibility to audiogenic seizures (AGS).  
This may be due to mouse brain development at this time.  It is estimated that onset of 
myelination in IC occurs at about P12 and auditory radiations and PV peaks at P16.  Studies have 
shown that GABA deficient mutant animals have lower seizure threshold and/or spontaneous 
seizures.  In propylthiouracil (PTU) audiogenic seizure mice, administration of PTU (an anti-
thyroid drug) at 0-19 days postnatal causes hypothyroidism during that time which is believed to 
cause GABA circuit defects in the mice, rendering them susceptible to audiogenic seizures 
(AGS) starting at around 7 weeks.  Administration of a GABA agonist/positive modulator was 
able to restore GABA inhibition in adolescence.  To determine if FDKOSe mice develop 
seizures similarly to MDKOSe, studies on PV+IN and GABAergic system defects in these brain 
areas need to be conducted. 
Even with SeH2O supplementation, FDKOSe mice showed increased percentage of 
ingWAT and gWAT deposits compared to their FWTnSe counterparts, but no significant 
44 
 
differences in fasting insulin levels.  If insulin secretion was affected, we expected there to be 
lower levels of insulin present in the groups that are defective.  But, if the glucose uptake 
mechanism is affected, then insulin levels may appear elevated or comparable between the 
groups.  As the fasting insulin levels were comparative between the groups a follow-up of fasting 
glucose and/or glucose tolerance test may need to be conducted to confirm the later affect.   
In mammals, white adipose tissue is used for energy storage in the form of lipids and is 
considered one of the largest endocrine organs involved in both immunity and metabolic 
mechanisms (108; 109).  An increase in subcutaneous fat normally occurs prior to abdominal 
(visceral) deposits (110) and has been shown to be an independent predictor of type 2 diabetes 
without the presence of insulin resistance (IR) (111).  Visceral obesity is an important 
determinate of the development of pathogeneses of chronic inflammation and insulin resistance 
(IR) leading to metabolic syndrome and increased risk of type 2 diabetes mellitus and 
cardiovascular disease development (108; 109; 112).  The increased fat deposits in FDKOSe 
could be evidence of the beginning of a metabolic deficit that appears mild at this age, under the 
current diet but further testing would be needed to determine this.   
In addition, the elevated serum Gpx3 levels in FDKOSe mice may also indicate the 
beginning of a metabolic deficit (Figure 3.11).  Gpx3 is an extracellular glutathione peroxidase 
that accounts for about 30% of Se in the plasma (113; 114). It has been found to be synthesized 
and secreted into the follicular lumen of the thyroid.  In the follicular lumen it is thought to 
modulate hydrogen peroxide (H2O2) supply, the rate limiting co-factor in TH biosynthesis, and 
catalyze thyroglobulin polymerization into a highly cross-linked, storage form (74; 115; 116).  It 
is possible that Gpx3 may be having an effect on TH by modulating its synthesis and storage but 
further investigation would be needed to evaluate this possibility.   
Alternatively, Gpx3 has also been implicated as a status marker in development of 
metabolic syndrome as increased serum levels of Gpx3 have been found in patients with this 
disorder (117).  In FDKOSe mice both ingWAT and gWAT deposit percentages are significantly 
increased.  Since increased subcutaneous fat deposits even without evidence of IR has been 
indicated to precede metabolic syndrome development, this seems to be the more likely 
explanation for the increased Gpx3 levels in these mice.  The mild phenotype may be due to the 
relatively young age of the mice tested and, as metabolic syndrome severity tends to increase 
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with age, a longer observation may be beneficial in confirming whether further metabolic 
disruption would develop. 
 
Conclusion 
Based on the data presented above, it is apparent that FDKOSe mice have a neurological 
deficit which becomes severe leading to seizure development if SeH2O is removed prior to age 
P37.  When SeH2O supplementation is removed at weaning, 83% of FDKOSe developed a 
severe neurological phenotype by 10 weeks of age.  FDKOSe mice had significantly increased 
percentage of ingWAT and gWAT fat deposits as well as serum Gpx3 levels which may indicate 
a metabolic component but it appears to be mild at this age as fasting insulin levels were 
unaffected compared to FWTnSe mice. Together, these results indicate that there is a window of 
development in which Se is important for FDKOSe mice to prevent severe neurological deficits. 
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Chapter 4: Competition between the Brain and Testes for 
Se in MDKOSe mice 
Introduction 
Se distribution in the body varies by tissue, with priority given to the brain and endocrine 
tissues (107), and this is also sexually dimorphic.  Females have been shown to have higher 
retention in all tissues except the brain, where it is similar in both sexes, and the reproductive 
organs, where retention is higher in the testes compared to ovaries (76; 107).  The similar Se 
brain levels appears to change in the DKOSe mice, as the Se concentration was found to be about 
27% higher in the females than males (Figure 4.1) which could be due to a change in retention, 
availability or turnover.  
  Testosterone is an androgen produced by the adrenal cortex and gonads that increases in 
concentration in males during puberty is testosterone (118).  It primarily affects the maturation 
and function of secondary sex organs, determination of male sexual characteristics, and is 
involved in tissue and muscle growth.  Males have three surges of testosterone production during 
development. In rodents, these occur before birth, right after birth and at puberty (119).  
MDKOSe mice have decreased survival, neurological dysfunction and onset of susceptibility to 
AGS, which occur around puberty at 8 weeks of age the same time as the reported testosterone 
surge to adult levels. Thus, we hypothesized that testosterone could possibly be an agonist in the 
production of the MDKOSe neurodegenerative state via its ability to increase cell metabolism 
and thereby oxidative stress.     
  In males, greater than 95% of testosterone is made in the testes.  Therefore, in order to 
determine if testosterone could be a factor in the MDKOSe neurological deficit development, we 
first castrated the male DKOSe, Sepp1KO, and WT mice and tested them for neurological 
impairment.  Then, we re-administrated testosterone to a group of castrated and sham operated 
mice to determine if testosterone could reverse the effects of castration and/or alter the MDKOSe 
phenotype. 
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Materials and methods 
Animals: Mice were generated, maintained, and samples collected as previously 
described in Chapter 2 with the exception of WT mice used in the MK-801 study. These mice 
were group housed until 8–10 weeks of age and then single housed 5 days before the onset of 
experiments.  Behavioral testing was conducted on adult mice between the ages of 9 and 15 
weeks during the light cycle. 
Diet:  A select group of animals were administered a low Se diet of 0.01 ppm selenium 
beginning at either weaning (WT MK-801 experiments) or at 10 weeks of age (Sepp1KO 
experiments).    
Castration and Sham Surgery: Four to five week old MWTnSe and MDKOSe mice were 
anesthetized and surgical area prepared. An abdominal incision was made near the groin area, the 
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Figure 4.1: Se Brain Concentrations in 
DKOSe Mice.  Brain Se levels in male and 
female DKOSe relative to MDKOSe (n=4, 
Student T-test **p=0.0011) 
Hypothesis:  Testosterone supplementation may exacerbate or potentially ameliorate the 
MDKO neurodegenerative phenotype. 
Aim:  Determine the neurological effects of testosterone in the MDKOSe phenotype. 
Significance:  Identifying the underlying factors and compensatory processes that are 
distinct in males versus females during childhood and adolescent development may provide 
new insights into potential therapeutic targets in cases of fetal and childhood Se deficiency. 
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tunica was pierced and the testes along with epididymis were exposed and removed. The incision 
was then sutured closed and animals received postoperative analgesic administration. Sham 
animals underwent the same procedure but testicles and epididymis were not removed.  
MK-801 drug treatment: At 6 weeks of age, select WT mice received intraperitoneal 
injections of PBS or MK-801 (Sigma-Aldrich; 0.2 mg/kg in PBS) for 5 consecutive days.  
Histology and immunohistochemistry: All were conducted as described in Chapter 3 
except for in immunofluorescence the appropriate AlexaFluor-labeled fluorescent secondary 
antibodies were used for visualization instead of DAB.  Perineuronal nets (PNNs) were labeled 
by incubation in a solution containing biotinylated Wisteria floribunda lectin (1:1000; Sigma, 
L1516), washed, and then incubated with fluorescent avidin (1:500; Vector Labs) for 
visualization.  
Silver staining: Silver staining was performed as described in Chapter 3. 
Protein extraction and immunoblotting: All were conducted as described in Chapter 3 
except relative protein levels were determined by dividing the optical density of the band 
representing the protein of interest by that of α-tubulin (loading control).  The mean normalized 
optical density for each protein of interest in sham DKOSe mice was recalibrated to equal 100. 
Antibodies: The primary antibodies used for immunohistochemistry were as follows: 
mouse anti-GAD67 (1:20,000; EMD Millipore, MAB5406), rabbit anti-PGC-1 (1:200; Santa 
Cruz Biotechnology SC-13067), rabbit anti-GFAP (1:2000; DAKO Z0334), goat anti-ApoER2 
(1:50; Santa Cruz Biotechnology SC-10113), rabbit anti-selenophosphate synthetase 2 (1:1000; 
Rockland 200-401-999), rabbit anti-parvalbumin (1:5000; Swant PV 25), and rabbit anti-c-Fos 
(1:5000; EMD Millipore PC38). The primary antibodies used for Western blotting were as 
follows: mouse anti-α-tubulin (1:5000; Novus Biologicals NB100-690), rabbit anti-PGC-1 
(1:1000; EMD Millipore AB3242), goat anti-glutathione peroxidase 1 (1:500; R&D Systems 
AF3798), rabbit anti-GPx4 (1:1000; Cayman Chemical 10005258), and rabbit anti-SelM (1:500; 
Sigma-Aldrich HPA019601).  
Gpx activity assay: Gpx activity was measured as described in Chapter 3 
Neuromotor and Behavioral tests:  All analyses were conducted as described in Chapter 
2 except the Open Field test for the testosterone re-administration group. The 2½ minute 
acclimation period was used in lieu of conducting a separate test. 
For the WT MK-801 study mice underwent the following additional test: 
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• Barnes Maze test for spatial learning and memory.  Assay was conducted as 
described previously (120). In brief, the maze consists of 40 equally spaced 
wholes on a white circular board, with a removable escape tunnel attached to one 
whole. Mice were trained to find the escape tunnel with two 3 minutes trials for 
10 days.  If a mouse failed to find the escape tunnel within the 3 minute period, it 
was placed in the escape tunnel by the researcher and allowed to stay there for 15 
seconds.  The latency to locate the escape tunnel and the number of incorrect 
holes checked (errors) before locating the escape tunnel were recorded.   
Se analysis: Se was measured using a modification of the fluorometric assay of Koh and 
Benson (1983) and Sheehan and Gao (1990). Briefly, tissue was predigested in nitric acid at 
150°C followed by digestion with perchloric nitric acid (1:4) solution at 190°C over a 1½   hour 
time period.  Solution cooled to 150°C, as it cooled 0.5 ml of concentrated HCl was added, 
samples were then maintained between 125°C and 150°C for 30 minutes. Next, 2 ml of 0.1 M 
EDTA and 0.5 ml of 2, 3-diaminonaphthalene were added, followed by 3 ml of cyclohexane and 
samples allowed to incubate at 60°C for 30 minutes. Fluorescence was then measured by a 
PerkinElmer LS 55 fluorometer and concentrations determined via comparison with a standard 
curve.  
Testosterone measurement: Blood was collected from adult mice via cardiac puncture 
during the early evening period (4:00–6:00 P.M.). Serum testosterone levels were then 
determined by means of a testosterone ELISA kit (Crystal Chem) pursuant to the manufactures 
instructions. 
Testosterone and Placebo Administration: Testosterone 60 day releasing pellets at 25 
µg/day and placebo pellets (Innovative Research of America, Testosterone and matching Placebo 
1.5 mg 60 day releasing pellets catalog # SA-151 and SC-111) were administered via 
subcutaneous insertion at between 5 to 6 weeks of age.  
Stereology: Analysis of cell density was performed on a Zeiss microscope (Axioskop2) 
equipped with Stereo Investigator software (MBF Bioscience).  An optical dissector (counting 
box) was used to count cells.  The retrosplenial granular cortex and IC were outlined using a 5 x 
objective at specified levels relative to bregma (retrosplenial granular cortex -1.46 mm, IC -5.02 
mm).  Optical fractionator analysis was conducted at high magnification (20 x objective) using a 
300 x 300 μm counting frame to quantify the number of positively labeled cells. At each 
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counting site, the mounted section thickness was determined. Mean section thickness was 
calculated by averaging all counting sites, and this value was used to determine the number of 
positively labeled cells per unit volume. For double-label experiments, parvalbumin (PV)-
positive cells (red) were counted first then the filter was switched, and WFA-positive cells 
(green) were counted by revisiting the same sites previously sampled. Finally, counting sites 
were revisited again and cells with overlapping markers (PV, WFA) were counted as PNN-
labeled PV interneurons. 
Quantification of immunohistochemistry and silver staining: Analysis were conducted as 
previously described in Chapter 3. 
Statistical analysis: All were conducted as described in Chapter 2. 
 
Results: Castration of Male DKOSe, Sepp1KO and WT Mice 
MDKOSe mice 
  We found that castration prevented severe neurological dysfunction in MDKOSe mice.  
Castrated MDKOSe mice had 100% survival at 10 weeks (Figure 4.2 A) with significant 
increases in motor coordination and locomotion (Figure 4.2 B and C).  They failed to develop 
audiogenic seizures (Figure 4.2 D).  When we examined the areas where neurodegeneration is 
normally observed in these mice (i.e. the inferior colliculus (IC) and decussation of superior 
cerebellar peduncle (XSCP)), neurodegeneration was not observed (Figure 4.3).  Brain Se levels 
were significantly increased in adult castrated mice (Figure 4.4 A), as well as, Gpx activity in 
both the whole brain and brain stem (Figure 4.4 B).  Castration seems to have promoted the 
maturation of parvalbumin expressing interneurons (PV+IN) as detected by a higher percentage 
of PV+IN enclosed by perineuronal nets (PNNs) (Figure 4.5), which are specialized extracellular 
matrix that enwrap PV+IN as they mature, thereby promoting interneuron maturation and 
synaptic network stability. 
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Figure 4.2:  Percent Survival and Rotorod, Open Field and Audio Open Field Behavior in 
Castrated MDKOSe Mice.  A. Survival curve of sham (n=31) and castrated (n=20) DKOSe 
mice.  B. Mean latency to fall off rotorod (Student t-test: t(22)=3.422 **p<0.01; sham n=7, 
castrated n=17).  C. Mean distance traveled during the open field test (Student t-test: 
t(20)=2.886 **p<0.01; sham n=9, castrated n=13).  D. Mean speed before 85 dB white noise 
and in the 10 second period after start of 85 dB white noise (Two-way ANOVA: Interaction 
F(1,19) =22.69 p<0.001; Sound F(1,19)=725.51 **p<0.001; Castration F(1,19)=7.232 p<0.05; 
sham n=5, castrated n=16).  
A B
C D Audio Open Field
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Figure 4.4:  Brain Selenium and Gpx Activity Levels in Castrated MDKOSe Mice.  A. 
Mean (±SEM) whole brain Se levels in male (n=4), castrated (n=5), and female (n=4) 
DKOSe mice (One-way ANOVA p=0.0001, Tukey’s post hoc *,** and *** p=<0.05); B. 
Mean (±SEM) normalized GPx activity in whole brain (n=4 or 5 per group) and brainstem 
(n=8 per group) of sham and castrated DKOSe mice, samples relative to sham samples. 
(Student t-test: whole brain t(7) =3.037, *p<0.05; brainstem t(14) =2.235, *p<0.05) 
A B
 
Figure 4.3:  Silver Staining Density in Castrated MDKOSe Mice.  A.  Representative 
images (20x) of silver stained sections from IC and XSCP of sham (left) and castrated 
(right) MDKOSe mice; B. Quantification of average optical density of IC and XSCP of 
sham (n=3) and castrated (n=3) (Student t-test: IC t(4)=3.422 *p=0.0052; XSCP t(4)=4.906 
*p=0.0080). 
 
A B
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MSepp1KO mice 
  When administered a Se-deficient diet, Sepp1KO mice develop neurological dysfunction 
(93).  Castration of Sepp1KO mice on a Se-deficient diet appeared to reverse this effect.  
Castrated Sepp1KO mice exhibited significantly better Rotorod performance than sham mice 
after five weeks of a Se-deficient diet (Figure 4.6 A) and none exhibited wild running nor seizure 
 
Figure 4.5:  Parvalbumin Expressing Interneurons in Castrated MDKOSe.  A. 
Representative immunofluorescent images of PV (red) and PNNs (WFA-labeled, green) 
from the IC of sham and castrated DKOSe mice. Yellow arrows indicate WFA-labeled PV 
interneurons in merged images. B. Mean (±SEM) density of PV interneurons per mm3. C. 
Mean (±SEM) density of PNNs (WFA-labeled) PV interneurons per mm3 (Student t-test: 
t(7)=2.446, *p<0.05; sham: n=4, castrated: n=5; Scale bar, 100 μm). 
Sham
Castrated
A
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response when tested in the AOF (Figure 4.6 B).  The IC and XSCP had significantly less silver 
staining, indicating neurodegeneration was diminished in these brain regions (Figure 4.7 A and 
B).  Gpx activity was significantly higher in the brain stem of castrated Sepp1KO mice compared 
to the sham operated mice with activity trending higher in the brain as a whole (Figure 4.7 C).  
Though castration appeared to be protective under Se-deficient conditions in these mice, this 
effect was not long-lasting as onset of neurological dysfunction was only delayed by three 
weeks. 
 
 
Figure 4.6: Weekly Rotorod and Audio Open Field Behavior in Castrated MSepp1KO on 
Se-deficient Diet.  A. Castration delays neurological impairment and neurodegeneration in 
Sepp1KO mice challenged with a Se-deficient diet.  A. Mean (±SEM) latency to fall off 
rotorod from 0 to 4 weeks on a low Se diet (Two-way ANOVA: time F(2,36)=6.661, p<0.01; 
interaction F(2,36)=3.788, p<0.05; Week 4 Student t-test: t(18)=2.954, *p=0.0106, n=10 per 
group) and (B) Mean (±SEM) speed before 85 dB white noise and in the 10 seconds period 
immediately after start of 85 dB white noise after 5 weeks on a low Se diet (n=10 per 
group) of castrated and sham Sepp1KO mice. (Two-way ANOVA: interaction F(1,18)=5.836, 
**p< 0.05; Post-sound t(18)=2.990, *p<0.05). 
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Figure 4.7: Silver Staining and Gpx Activity Levels in Castrated Sepp1KO Mice on Se-
deficient Diet.  A. Representative images of silver-stained brain sections containing the 
XSCP (left) and the IC (right); Scale bar, 200 μm.  B.  Mean (±SEM) optical density of 
silver staining in sham (n=5) and castrated (n=4) Sepp1KO mice (Student t-test: IC t(7)= 
2.415,* p< 0.05; XSCP t(7)=2.671, *p<0.05).  C. Mean (±SEM) normalized GPx activity in 
brainstem and whole-brain samples (Student t-test: brain stem t(4)=7.340, *p<0.01, n=6 per 
group). (CIC=Central nucleus of inferior colliculus; ECIC=external cortex of inferior 
colliculus.).  
A
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MWT mice 
  In addition to DKOSe and Sepp1KO mice, we castrated wild type mice (WT) and 
exposed them to dizocilpine maleate (MK-801) at puberty.  MK-801 is a non-competitive 
NMDA receptor antagonist which would elevate oxidative stress, causing neurotoxicity.  It has 
also been reported to impair maturation of GABAergic neurons (121).  Castrated WT MK-801 
mice had improved spatial learning, as tested in the Barnes maze (Figure 4.8), and trended to 
better performance on the Rotorod (Figure 4.9 A) compared to sham WT.  Their Gpx activity 
levels were significantly elevated (Figure 4.9 B) and PV+IN density was increased in the regions 
the retrosplenial cortex normally affected by the MK-801 neurotoxin (Figure 4.10). 
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Figure 4.8: Barnes Maze Behavior in Castrated WT Mice Administered MK-801.  A. 
Mean (±SEM) latency to locate the escape tunnel during Barnes maze training (Two-
way ANOVA: primary latency F(4,108)= 71.87, p< 0.0001).  B. Mean (±SEM) number of 
incorrect holes checked before locating the escape tunnel during training (Two-way 
ANOVA: primary errors F(4,108)=71.87, p<0.0001).  C. Mean (±SEM) latency to locate 
the escape tunnel during trial block 3 (p<0.1123). D. Mean (±SEM) number of incorrect 
holes checked before locating the escape tunnel during trial block 3 (One-way ANOVA: 
primary errors F(2,27)=3.930, *p<0.05 compared with MK-801 group; n=10 per group). 
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Figure 4.9:  Rotorod Behavior and Gpx Activity Levels in WT Mice Administered MK-801.  
A. Mean (±SEM) latency to fall off Rotorod. B. Mean (±SEM) normalized GPx activity in 
samples from cortex, hippocampus, and brainstem (One-way ANOVA: Cortex F(2,11)=6.440, 
*p< 0.05; n=4 per group). 
A B
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Figure 4.10: Parvalbumin Expressing Interneurons in WT Mice Administered MK-801.  
A. Representative immunofluorescent images of PV (red) and WFA (green) from the 
retrosplenial cortex. Yellow arrows indicate WFA-labeled PV interneurons in merged 
images.  B. Mean (±SEM) density of PV interneurons per mm3 (One-way ANOVA: 
F(2,15)=4.817, *p<0.05 compared with Control group). C. Mean (±SEM) density of WFA-
labeled PV interneurons per mm3. Scale bar, 100 μm.  
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  Thus, castration seems to be neuroprotective.  It appears to rescue the MDKO phenotype, 
delay neurological effects of a Se deficient diet in MSepp1KO mice, and provides partial 
protection from the neurotoxin, MK-801, in WT mice.  The main neurological effect of 
castration observed was the promotion of PV+IN maturation thereby promoting normal 
excitatory/inhibitory balance.  This finding, along with the increased Se concentration and Gpx 
activity in the brain, indicate that the brain and testes may compete for Se supply in the absence 
of Scly and Sepp1, which may lead to the male sex specific phenotype. 
 
Results: Testosterone Re-administration in MDKOSe Mice 
Upon further characterization of the MDKOSe mice, we found that disrupted Se 
metabolism appears to be preceded by signs of reactive gliosis at 4 weeks of age (data not 
shown), weeks prior to the apparent GABAergic system deficits and loss of PV expression seen 
in adult MDKOSe mice at 8 weeks of age.  This early onset of disruption in certain brain areas 
has been previously reported in Sepp1KO mice (122).  As stated above, castration seems to 
rescue the MDKOSe phenotype and delays the onset of motor dysfunction in MSepp1KO mice 
on a Se deficient diet.  When investigating Se levels, we found that castration appears to 
significantly increase Se concentrations in the brains of MDKOSe mice (Figure 4.4 A) but when 
comparing Se concentrations in the testes, although MDKOSe had significantly reduced Se 
levels compared to MWT, Se levels were not significantly different from those found in male 
Sepp1KO that do not develop a neurological phenotype (Figure 4.11).  Therefore, the apparent 
protection from castration seems to be due to increased Se availability in the brain (102) but the 
permanent susceptibility to Se deficiency in these mice implicates a developmental process that 
is possibly being disrupted prior to weaning at 4 weeks of age.   
  Testosterone has been shown to reverse the decreased cellular metabolism in castrated 
rats (123). The effect of testosterone may increase/accelerate the degeneration in the MDKOSe 
mice due to increased oxidative stress associated with increased metabolism. This would be 
manifested in reversing the protective effects of castration in neuromotor and behavior tests.  A 
detrimental effect of testosterone replacement would have implications in hormone replacement 
therapies in males with compromised anti-oxidative defense systems, as oxidative status may 
need to be taken into consideration prior to prescribing testosterone as a treatment. Alternatively, 
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if testosterone replacement does not exacerbate the neurological phenotype, this would imply 
that the effects of castration stem from eliminating competition for Se between brain and testes. 
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Figure 4.11: Testes Se Concentrations in Male WT, Sepp1KO, 
and DKOSe Mice.  Mean (± SEM) Se levels relative to MDKOSe 
in testes of MWT (n=4), MSepp1KO (n=6) and MDKO (n=4) 
mice (One-way ANOVA p=0.0001, Tukey’s post hoc * and ** 
p=<0.05). 
 
Hypothesis:  Protective effects of castration are due to either or both of the following: 1) the 
action of testosterone in brain development; and/or 2) competition between brain and testes 
for available Se when the trace element is limited. 
Aim:  Determine if MDKOSe phenotype is due to testosterone or brain Se status effect. 
Significance:  Identify potential risk factors that may need to be considered in adult 
hormone replacement therapies. 
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Preliminary group-housed mice 
  Preliminary data revealed that at puberty there was a reduction in average serum the 
testosterone levels in MDKOSe mice compared to MWT and MSepp1KO mice, although the 
differences did not reach statistical significance (Figure 4.12 A).  When comparing non-alpha 
male testosterone levels between group-housed mice, although MDKOSe were trending to lower 
testosterone levels then the other groups of non-alpha males this was not significant (Figure 4.12 
B).  No significant differences were found when comparing DKOSe males that developed 
audiogenic seizures and those that do not (Figure 4.12 C) but it appears that the DKOSe alpha 
males (males with the highest testosterone levels) fare better in retaining motor coordination at 7 
weeks of age than their cage mates (Figure 4.12 D).  Mice in this study were group-housed and 
alpha male mice were not analyzed separately, thus conclusions on the correlation between 
testosterone levels and neurological impairment are premature.  Therefore, we conducted 
experiments where we re-administered testosterone to castrated and sham operated MDKOSe 
mice along with one group of castrated MDKOSe mice taken off of SeH2O a few days after 
castration, at postnatal day 37 (MDKOSe-Cast-NoSeP37).  
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Figure 4.12: Testosterone Levels in Male WT, Sepp1KO and DKOSe Mice. A. Mean (± 
SEM) testosterone levels in male WT (n = 5), Sepp1KO (n = 5), and DKO (n = 4) mice; B. 
Mean (± SEM) testosterone levels in group housed, age matched male WT, Sepp1KO, and 
DKOSe males (each group consisted of 1 cage with n=4 to 5 mice); C. Mean (± SEM) 
testosterone levels in male DKOSe alpha (MDKOSe Alpha, mice with the highest 
testosterone concentration), male DKOSe mice that developed seizures (MDKOSe Seizure) 
and male DKOSe that did not develop seizures (MDKOSe Non-seizure) (Alpha, n=4;Non-
seizure, n=6; Seizure, n=5); D. Mean (± SEM) latency to fall off Rotorod at 5, 6 and 7 weeks 
of age for alpha male DKOSe (MDKOSe Alpha, mice with the highest testosterone 
concentration), male DKOSe that did not develop seizures (MDKOSe Non-seizure) and male 
DKOSe mice that developed seizures (MDKOSe Seizure) (Alpha, n=4; Non-seizure, n=6; 
Seizure, n=5) (each group consisted of 1 cage with n=4 to 5 mice). 
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Testosterone re-administration to castrated and sham-operated MDKOSe Mice 
  Testosterone supplementation was able to raise the levels of testosterone in castrated and 
sham MDKOSe mice, with sham supplemented testosterone levels being the highest (Figure 
4.13).  The levels approached those seen under normal conditions.  This was expected as sham 
mice still had the ability to produce testosterone due to intact testes in addition to the testosterone 
re-administration.  There appears to be no change in the performance on the Rotorod nor in the 
Open Field tests in the castrated mice.  Sham mice on testosterone supplementation had 
significantly better motor coordination, as tested by Rotorod, compared to the placebo group 
(Figure 4.14 A).   There were no significant differences in locomotion average distance (Figure 
4.14 B) nor average speed (Figure 4.14 C) but there was a 37% decrease in seizure occurrence in 
testosterone supplemented sham mice (Figure 4.14 D) indicating that testosterone was protective 
in this group.   
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Figure 4.13: Testosterone Levels in 
Testosterone Supplemented MDKOSe Mice.  
Serum testosterone levels in testosterone and 
placebo supplemented castrated and sham 
operated MDKOSe mice (Two-way ANOVA 
Condition F(1,22)=7.18, p=0.0137; 
Supplementation F(1,22)=9.93, p=0.0046; 
Bonferroni posttests **p<0.001). 
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SeH2O removal from castrated MDKOSe mice at P37 
  When we examined the castrated group that was taken off SeH2O at P37 (MDKOSe-
Cast-NoSeP37), it appeared that prepubescent castration attenuated the need for high Se 
supplementation in these mice.  On Rotorod testing, they were able to maintain a better weekly 
performance than MDKOSe mice, reaching significantly better levels at 10 weeks (Figure 4.15 
A) and none developed audiogenic seizures (Figure 4.15 B).  Signs of reactive gliosis were not 
observed in the IC nor XSCP (Figure 4.16 A, B and C) although there were no significant 
differences in whole brain nor brain stem Gpx activity compared to MDKOSe mice (Figure 4.16 
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Figure 4.14: Rotorod, Open Field and Audio Open Field Behavior in Testosterone 
Supplemented MDKOSe Mice.  Rotorod mean latency to fall (A), acclamation period 
average distance traveled in 2 ½ min prior to sound (B), and average speed 2 ½ min prior 
(PreSpeed) and 10 s after (PostSpeed) 85dB white noise played (C). D. Percentage of 
animals that had seizures by P70 of MDKOSe-Cast P, Cast T, MDKOSe-Sham P and 
Sham T mice (Two-Way ANOVA Rotorod p=0.0049; Open Field p=<0.0001; Audio 
Open Field p=0.0020 Bonferroni *p=<0.05; **p=<0.01; ***p=<0.001). 
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D).  Together, these data indicate that the neuroprotective effect of castration stems from the 
elimination of the testes as a competitor for Se supply under conditions of compromised Se 
metabolism largely independent of any effect on testosterone levels. 
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Figure 4.15: Effect of SeH2O Removal at P37 on Rotorod and Audio Open Field Behavior in 
Castrated MDKOSe Mice.  A.  Rotorod mean latency to fall from 6 to 10 weeks of age and (B) 
average speed 2½ minutes prior (PreSpeed) and 10 seconds after (PostSpeed) 85 dB white 
noise played (Two-way ANOVA: Interaction F(2,50)=3.01 p=0.0585; Genotype F(2,50)=3.10 
p=0.0537; Sound F(1,50)=1.50 p=1.51; Bonferroni post-test *p<0.05, **p<0.01) of MWTnSe, 
MDKOSe and MDKOSe-Cast-NoSeP37 (N=6). 
67 
 
 
 
Figure 4.16: Effect of SeH2O Removal at P37 on Glial Fibrillary Acidic Protein (GFAP) 
Immunoreactivity and Brain Gpx Activity Levels in Castrated MDKOSe Mice.  A. Select images 
of IC and XSCP of MWTnSe, MDKOSe-Sham P, MDKOSe-Sham T, MDKOSe-Cast P, 
MDKOSe-Cast T and MDKOSe-Cast-NoSeP37 mice with quantification of average optical 
density, IC (B) and XSCP (C) (One-way ANOVA: IC p=0.0069, Tukey’s post hoc t(21)=5.286, 
*p<0.05; XSCP p=0.0359, Tukey’s post hoc t(21)=4.560, *p<0.05; n=3-6 mice per group).  D. 
Gpx Activity in the whole brain and brain stem of MWTnSe, MDKOSe and MDKOSe-Cast-
NoSeP37 mice (One-way ANOVA: WB p<0.0001; BS p<0.0003; CEB p=0.0002; Tukey’s Post 
Hoc Test ****p<0.0005, ***p<0.005; n=4-6 mice per group). 
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Discussion 
  Se distribution in the body varies, with priority given to the brain and endocrine tissues 
(91).  Brain Se status appears to be independent of plasma Se status when Sepp1 is expressed in 
the brain (40), whereas, the lack of Sepp1 or its receptor, ApoER2, leads to the development of 
neurological dysfunction and deficits in spermatogenesis upon the administration of a Se-
deficient diet (93; 124).  When both Sepp1 and Scly are deleted, male mice exhibit decreased 
survival and severe neurological impairments (2).  Herein, we show that castration has a 
neuroprotective effect in both the Sepp1KO and DKOSe phenotypes.  Castration rescued the 
MDKOSe phenotype, delayed the neurological effects of a Se deficient diet in MSepp1KO mice 
and provided a partial protection from the neurotoxin, MK-801, in MWT mice.  When 
testosterone was re-administered to castrated mice, there was no significant effect but it did 
appear to be beneficial to sham operated mice.  This would seem to indicate that the brain and 
the testes compete for Se under Se deficiency thereby leading to the sex-specific phenotype of 
the MDKOSe mice. 
Previous studies have shown that the brain has priority over the testes for Se supply.  
Using 75Se, it was demonstrated that in Sepp1KO mice on a Se deficient diet the Se 
concentration in testes decreased to about 19% of wild type (WT) whereas the brain Se 
decreased to about 46% of WT.  When Se is re-administrated in the diet at a level 20 fold higher 
than the Se deficient dietary requirement of 0.1 ppm, brain levels return to normal (WT) whereas 
testes levels did not (84).  In both the 75Se study and ours it is important to note that although the 
brain has priority over the testes when Se is deficient, the testes still maintain a certain level of 
Se even when the brain Se levels are decreased.   
It is known that Se is important for sperm development as one selenoprotein, Gpx4, is 
incorporated as a structural component of sperm (125).  It is possible that the uptake of Se from 
circulation to the testes for sperm development at puberty causes just enough Se to be diverted 
from the brain to result in the neurological phenotype.  Our results seem to indicate this is the 
case as MDKOSe-Cast-NoSeP37 mice appear to not need the SeH2O supplementation.  
The gonads have two functions: steroid hormone production, i.e. secretion of cholesterol-
derived steroid hormones under control of the hypothalamo-pituitary axis (HPA), and 
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gametogenesis.  Sex steroid hormones produced in the gonads are made from cholesterol.  
Cholesterol accumulates in the brain from birth to adolescence with low turnover and minimal 
loss in adults (126).  The majority is found in myelin. It can be obtained through diet (i.e. low 
density lipoprotein (LDL)) or by de novo synthesis in the ER.  The blood brain barrier prevents 
lipoprotein cholesterol uptake from circulation so the brain relies primarily on de novo synthesis. 
The testes, on the other hand, rely on 50% LDL uptake and 50% de novo synthesis.  Ovaries rely 
primarily on LDL uptake (127).  Free Se has been said to bind lipoproteins (e.g. very low density 
lipoprotein (VLDL) and LDL) which allow transport through blood and membranes via trans-
membrane proteins (8).  Due to the lack of the Se specific transporter Sepp1, other mechanisms 
of Se uptake are in effect.  The ability of the testes to uptake LDL to a greater extent than the 
brain is just one possibility of how Se may be diverted to the testes.  Investigation into alternative 
methods of Se transport in the absence of Sepp1 would provide further insight into this matter. 
Testosterone does not reverse the effects of castration but proves to be beneficial, though 
not preventative, in sham MDKOSe mice.  In the brains of males, testosterone is converted to 
estradiol and dihydrotestosterone (DHT) with actions that can be region specific (128).  In aging 
men, brain levels of testosterone and its metabolites e.g. DHT and estradiol, decrease with age, 
termed andropause (129).  Decreased testosterone has been indicated as a risk factor that 
precedes metabolic syndrome and the development of cognitive neuropathies (130; 131).  
Alternatively, increased testosterone has also been negatively associated with cognitive 
impairments in Caucasians with high oxidative stress status (132) and adverse cardiovascular 
events (133).  In rats, testosterone deficiency leads to decreased mitochondrial gene expression 
and therefore decreased metabolism in the hippocampus, thus demonstrating its effect on energy 
metabolism through alterations in mitochondrial gene expression (123).  
Reactive oxidative species (ROS) are normal byproducts of energy metabolism, and 
abnormal levels can lead to oxidative stress, a risk factor in neurodegeneration.  We 
hypothesized that testosterone may contribute to the MDKOSe phenotype due to its potential 
effect on energy metabolism.  To the contrary, this does not appear to be the case.  Testosterone 
had no effect on castrated mice.  It appears to be beneficial in sham-operated mice but its effects 
were not sufficient to overcome the apparent deficits due to Se being diverted from the bran to 
the testes. 
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Disruption of GABAergic inhibition seems to be the main neurological effect leading to 
the development of audiogenic seizures in MDKOSe mice.  This is consistent with other studies 
demonstrating that diminished GABAergic inhibition in the inferior colliculus is associated with 
audiogenic seizures (134).  Our findings indicate that redox imbalance impedes the development 
and function of PV+IN.  PV+IN are a subclass of GABAergic cells that synchronize activity 
within populations of principal neurons (135). They have high metabolic demands making them 
particularly susceptible to oxidative stress (136).   As they mature, PV+IN are encapsulated by 
PNNs, a specialized extracellular matrix. PNNs are believed to limit plasticity and maintain 
excitatory/inhibitory balance upon neural network maturation and possibly serve as a protective 
barrier against oxidative stress (137; 138).  In our study, the density of the PV+IN and PV+IN 
with PNNs appeared normal at 4 weeks of age but this was not the case at 8 weeks of age.  This 
indicates that the maturation of PV+IN was impaired.  Moreover, castration was found to 
promote PV+IN maturation and prevent audiogenic seizures. Together, it appears that there is a 
critical threshold in which decreased Se and therefore, selenoprotein levels in the brain, causes 
PV+IN dysfunction to occur, leading to seizure development and neurodegeneration.  As a 
follow-up to this study, the impact on seizure threshold in the presence of varying concentrations 
of GABA agonist/modulators could be used to further probe the functional GABAergic defects 
in the DKOSe mice.   
Conclusion 
  MDKOSe mice exhibited severe neurological dysfunction and neurodegeneration in brain 
nuclei and tracts involved in auditory and motor pathways, with GABAergic system defects in 
the IC (2).   Preadolescent castration rescued the MDKOSe phenotype and eliminated the need 
for SeH2O supplementation in MDKOSe adults.  It delayed the onset of neuromotor deficits in 
MSepp1KO mice on a Se deficient diet and was protective of MWT mice exposed to MK-801 
neurotoxin.   Testosterone re-administration to sham-operated mice appeared to be beneficial but 
not preventative.  Together, these results suggest that there is a critical time frame in which 
selenium is essential for the prevention of adolescent and adult neurological impairment in males 
and that males may have a greater need than females for Se during the course of their sexual 
reproductive period due to the need for selenium in the testes. 
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Chapter 5: Conclusions and Future Directions – potential 
model for the study of ictogenesis and novel drug testing 
Introduction 
Seizures can spontaneously develop in both male and female DKOSe mice.  This 
spontaneous development is due to a nutritional deficiency caused by a deficit in the metabolism 
of the micronutrient Se, and it does not affected all mice equally e.g. 75% of males and 83% of 
females by ten to twelve weeks of age.  This provides three key areas for the study of seizure 
development: spontaneous seizure occurrence, nutritional influence, and influence of sex.   
  Our results indicate that there is a critical time point in which Se is essential for the 
prevention of neurological impairment in both male and female DKOSe mice.  MDKOSe may 
have a greater need for Se during the course of their sexual reproductive period due to 
competition between the testes and the brain for Se.  Disruption of the maturation of GABAergic 
inhibition seems to be the main neurological effect leading to the development of audiogenic 
seizures in MDKOSe mice which can be rescued with preadolescent castration.  Castration 
delays onset of neuromotor deficits in MSepp1KO mice on a Se deficient diet and is protective 
of MWT mice exposed to the neurotoxin dizocilpine maleate (MK-801).  Testosterone re-
administration to sham-operated MDKOSe mice appears to be beneficial but not preventative. 
  The specific deficits in behavioral tests and underlying GABAergic system maturation 
disruption could allow DKOSe mice to potentially serve as a model for the study of ictogenesis.  
Further investigation into the roles of selenoproteins at key points of development would be 
beneficial in determining dietary supplementation requirements.  This knowledge can then be 
used to optimize individualized nutrition in both humans and animals, thereby having potential 
application to preventing disease pathology in the case of Se deficiency and as a potential model 
for targeted therapeutic agents in epileptic patients. 
 
Seizures 
 Seizure disorders are considered a major type of neurological diseases (139).  Typically, 
we think of seizures as convulsions where the body shakes uncontrollably, but this is only a 
symptom of some types of seizures.  A seizure, as defined by Medline Plus, is “the physical 
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findings or changes in behavior that occur after an episode of abnormal electrical activity in the 
brain” (140).  This can range from a brief, 1 second action, to prolonged 1 to 2 minute actions.  
Convulsions associated with seizures depend on the area of the brain where abnormal activity 
occurs and if it spreads to other areas or remains focal.   
 Seizures have been categorized into several types.  Generalized seizures normally begin 
in both hemispheres of the brain.  These include tonic-clonic seizures (grand mal seizures) where 
there is a stiffening phase followed by a jerking phase which can last up to two minutes, and 
absence (petit mal) seizures involving brief periods of loss of consciousness followed by 
returning to  normal cognition.  Sometimes they are accompanied by repetitive blinking and 
rolling of the eyes.  Myoclonic seizures that last only 1 to 2 seconds and may include a jerk or 
loss of consciousness but are difficult to identify due to the brevity of the seizure, and atonic 
seizures where there is a sudden loss of muscle tone leading to a falling or “dropping” of the 
person (141). 
 Partial seizures (focal seizures) normally start in a specific area of the brain and may 
remain limited to that area or spread to other areas of the brain.  If they spread to the other 
hemisphere of the brain then they may lead to a secondary generalized seizure as described 
above.  These are the most common type of seizures found in adults with epilepsy (142; 143).  
They can involve any movement, sensory or emotional symptoms depending on which area of 
the brain that is involved.  These seizures can be “simple” where they last only 30 to 60 seconds 
with consciousness retained or “complex” lasting 1 to 2 minutes with impairment or loss of 
consciousness. 
 Other seizure types include gelastic and dacrystic seizures. These seizures are commonly 
overlooked due to their unusual manifestations (144).  Gelastic seizures manifest as bouts of 
uncontrollable laughter and/or giggling.  They cause facial contractions that cause the person to 
look like they are smiling.  Dacrystic is when the vocalization sounds like crying and the facial 
contractions cause the person to look like they are frowning.  These are commonly overlooked in 
children unless other clinical signs (auras) that occur prior to seizure occurrence, such as eye 
dilation, are recognized.  Usually these seizures are a pre-development of other types of seizures 
such as absence, complex partial or generalized seizures.  These types of seizures may be 
triggered by hypothalamic hamartomas (benign tumor of hypothalamus).  If detected early, 
therapy can be administered to reduce the tumor size to avoid further progression. 
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 Non-epileptic seizures (NES) are not caused by a central nervous system (brain) 
abnormality (145).  They consist of two types, organic or psychogenic.  Organic NESs are 
physical in nature, e.g. low blood sugar or changes in heart function.  Their symptoms can be 
syncope (fainting) or symptoms similar to one of the other seizures mentioned above.  Normally, 
once the underlying cause is corrected the seizures can be controlled or stopped.   
 Psychogenic NESs contain a mental health element such as emotional stress or other 
anxieties.  These include traditional seizure type symptoms and panic attacks.  They are divided 
into dissociative (involuntary) or factitious (under conscious control).  Regardless of their causes, 
they are normally “sudden, short and cause a change of person’s awareness” (145).  Behavior 
modification therapies are normally used in treatment of these types of seizures.     
 As mentioned above, seizures can be a one-time occurrence or epileptic in nature (e.g. 
epilepsy).  According to the World Health Organization, epilepsy affects about 50 million people 
worldwide and six cases out of ten have no known cause (146).  Those with a known cause are 
sometimes considered secondary epilepsy because the seizure is secondary to a primary cause 
such as brain damage and/or malformation; brain trauma due to stroke or blunt trauma; tumor or 
genetic defect.   
 The most common type of epilepsy is temporal lobe epilepsy (TLE) (142).  TLE is 
associated with the medial temporal lobe regions and patients with this type of epilepsy normally 
do not respond to clinical treatment (147).  The temporal lobe is known to be involved in visual 
memory retention, sensory input processing, language and emotion together with the medial 
temporal lobe containing the amygdala, brainstem, hippocampus and neocortical regions.   Since 
most patients do not respond to drug treatment, surgery is usually used to remove the affected 
brain areas.   
 Currently, it is believed that 70% of patients with epilepsy will respond to treatment 
(146).  Treatments include antiepileptic drugs which, if taken regularly, have been shown to 
prevent seizures in 50% of patients and reduce seizure activity in another 20% (148).   For some 
patients, after taking antiepileptic drugs for several years they can be weaned off to be seizure 
free without medication.  For those that do not respond to the antiepileptic drugs, other therapies 
such as electrical/magnetic stimulation, ketogenic diet, surgery and behavioral modification can 
be implemented with or without antiepileptic medications.    
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 Electrical/magnetic stimulation is where electrical or magnetic pulses are used to 
stimulate brain activity.  Though the current studies using this method seem to be focused more 
on mental disorders such as severe depression, it has been found to help some people with 
epilepsy.  Vagus nerve stimulation, wherein a device is implanted that sends 30 second pulses 
through the left vagus nerve, can alter certain neurotransmitters in the areas of the brain that 
affect mood and sleep as well as stimulating the major organs such as heart, lungs and intestines 
(149). 
 Diet is also used for treatment of some types of seizures.  The link between nutrition and 
epilepsy has yet to be elucidated completely and is complicated by the possibility of multiple 
unknown causes (150).  Some people are able to control seizure by fasting (151).  It has now 
been found that about 1/3 of children placed on a ketogenic diet become seizure free.  The 
ketogenic diet mimics starvation forcing the body to burn fat as its main source of energy.  
Children are normally placed on this diet and weaned off antiepileptic drugs over a two-year 
period.  If successful, the child can then be returned to a normal diet, seizure free or with 
successful medication control. 
 Surgery is normally used as a last resort when the individual does not respond to 
available treatments and the seizure arises from a focal area that can be specifically identified 
and removed.  Like all treatments, surgery does not work for some patients as the source of the 
seizures may migrate to the opposite lobe which cannot be removed without significantly 
altering the patient’s mental capacity. 
 Behavioral modification therapies have been used by many people with mixed results.  
They are considered complementary approach as they may help some people improve their 
quality of life (152).  This type of approach is used most often in NES patients wherethe cause is 
voluntary or learned, and can be reversed by changes in mental thought processes.  
 Overall, people who have epilepsy, if given access to treatment therapy, have a good 
chance (70%) of controlling their seizures.  But there is still a need for improvement in current 
therapies and to find new therapies for those that do not respond to existing treatments.  When 
setting up a study that explores treatment options, current models use one of two hypotheses, 
recurrent excitation, which assumes hyper excitability due to abnormal excitatory circuitry, or 
inhibition, the loss of inhibitory neurons.  From these hypotheses, researchers have developed 
two types of animal models, post-status epilepticus (severe insult model due to chemo-
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convulsant, electrical stimulation, etc.) and kindling models (repetitive exposure to mild 
electrical stimulation leading to seizure development).  With these models, researchers have been 
looking at new potential therapies such as cell therapy (cell grafts), neuroprotective agents and 
other biological agents that might help to restore normal function of the affected areas.  
 
Animal Models in Basic Research 
In basic research, the application of the knowledge obtained is not always readily 
apparent.  It may take years of successive studies, sometimes from multiple independent labs, 
before basic research leads to beneficial treatments that can be applied in clinical settings.  Part 
of this process involves the use of animal models.  By using animal models one can study 
molecular pathways that contribute to diseaseoutcomes and pathology in vivo.  Targets of 
cellular mechanisms can then be investigated to determine if a modification (e.g. administration 
of a novel drug, gene editing or surgery) can be used as a therapy without causing adverse side 
effects. 
The mouse (Mus musculus) has been used as the animal model in basic research for many 
human diseases.  Mice are mammals with a genome of approximately 30,000-40,000 genes, 99% 
of which have human homologues (153).  Mice have a short gestation period (about a month) 
and relatively short lifespan (1-2 years) which make them ideal for studying development, 
puberty and some properties of aging in a reasonable timeframe.  There are multiple resources 
available that help make mouse-human comparisons including Translating Time 
(http://www.translatingtime.net/) and the Allan Brain Atlas (http://www.brain-map.org/).  In 
addition, due to advances in gene manipulation techniques, “custom” mice are becoming more 
common and can be bred to investigate the function of specific genes.   
 An area of medical research that has made advances using animal models is the study of 
potential treatments for epilepsy and seizure disorders.  The brain is a dynamic environment 
involving a complex interaction of multiple molecular and cellular components which cannot be 
completely duplicated by current in vitro techniques.  For such a dynamic system, mouse models 
have been useful tools.  Detailed reviews by Loscher (154), Auvin (155) and Grone and Baraban 
(156) discuss the current models used for research in this area.  In general, these models fall into 
two categories, induced or genetic.  Induced models require the administration of external stimuli 
or insult to normal mice allowing researchers to produce both acute and chronic seizure 
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disorders.  The development of genetically altered animals have allowed for the modeling of 
known epileptic genes (156).   
 But, like models of other diseases, currently there is no single model that has been able to 
completely represent all features of human seizure disorders.  One of the limitations arising from 
induced models is that most human epileptics have multiple spontaneous seizures indicating that 
the ictogenesis arises possibly from a different mechanism than the one produced by electrical or 
chemical induction.  Genetic models give insights to inheritable phenotypes but do not 
necessarily address all aspects of the condition or epilepsy of idiopathic origin.  
When interpreting animal studies, investigators must keep in mind that most animal 
models do not develop all of the characteristics found in human epileptic seizures (157; 158; 
159).  This is complicated by the fact that normally the cause of the human condition is not fully 
known and therefore, it is unknown how much or little the animal model mimics the clinical 
condition.  For these reasons it might be better to think of animal models as partial or 
“incomplete” models.  They can be used to investigate some of the disease mechanism thereby 
elucidating specific parts of the disease process.  The more one is familiar with the aspects of the 
disease state in the animal model the easier it will be to interpret the experimental results and 
develop relevant treatments. 
Even with incomplete models, progress has been made to develop treatments for patients 
with seizure disorders.  The current models have led to the development of anticonvulsant drugs 
to which 50% of patients respond positively and seizure reduction is seen in another 20% (148).  
Room for improvement is still evident as there are still no treatment options for 30% of patients 
and 20% of those on active treatment still suffer from some type of seizure activity.  Continued 
basic research on the ictogenesis as well as the mechanisms by which anticonvulsants may be 
able to suppress seizure activity is needed.  This will lead to the enhancement of experimental 
interpretation and finally better treatment options to those who suffer from seizure episodes. 
 
Selenium and epilepsy 
 Selenium has become increasing thought to play a role in the pathologenesis of epilepsy 
due to the role of selenoproteins in defense against oxidative stress. In animal models, oxidative 
stress imbalance has been shown to be attenuated upon selenium supplementation (160; 161; 
162; 163; 164; 82) with selenium deficiency leading to increased seizure susceptibility (2; 70; 
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165). Patients with epilepsy have been found to have oxidative stress abnormalities such as 
decreased antioxidants and increased lipid peroxidation (166).  Studies of febrile seizures in 
children have indicated decreased selenium serum levels (167; 168; 169; 10; 11) with some 
studies showing an attenuation of seizure activity upon selenium supplementation (9). 
 
Sepp1 and Scly Double Knockout: potential model for studying seizure development and 
epilepsy 
As stated earlier, six out of ten patients with epileptic seizures have no known cause and 
most have multiple spontaneous seizures.  Two hypotheses for the causes of epilepsy are 
abnormal excitatory or inhibition circuitry.  Induced and genetic animal models of seizures have 
been developed to study these aspects but still 30% of patients do not respond to current 
therapies.  In DKOSe mice, both male and female mice develop seizures and therefore they may 
serve as a potential animal model for studying seizure genesis and for therapeutic drug testing. 
 In compiling all our data to date, we have the following information that can be used for 
investigational purposes: 
 Behavioral  (Figure 5.1) and body composition (Figure 5.2):  Motor cordination is 
expected to decrease as DKOSe mice age, with a percentage of mice in each sex that will 
develop seizures by P70.  For MDKOSe mice, the percentage that will develop seizures is about 
73-77% between 8 to 12 weeks of age with approximately 40% requiring euthanasia prior to 10 
weeks of age.  Decrease in motor coordination begins at about 6 weeks of age.  This is 
accompained by a wobbly or abnormal gait.  Weight loss along with decreasing food and water 
intake will commence approximately a week prior to seizure development.  Aura and ictal stages 
are of consistent duration with the postictal stage duration lengthening as the condition of the 
mice deteriorates.   Castration appears to attenuate the need for SeH2O supplementation after age 
P37, indicating the testes ability to divert Se from the brain. 
 In FDKOSe mice, decreases in motor coordination starts at 7 weeks of age.  This 
becomes significantly different from FWTnSe mice by 10 weeks of age and is accompanied by 
significant weight gain.  When SeH2O supplementation is removed at weaning (P22) about 83% 
will develop a neurological phenotype by 10 weeks of age.  Removal of SeH2O supplementation 
at adulthood (P37) appears to not lead to seizure development but it is still unknown whether this 
would affect them in other aspects e.g. fertility.  As the FDKOSe mice have not been as 
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extensively studied as the MDKOSe mice, further and more comprehensive studies on 
parameters such as food and water intake, weight change and signs leading up to seizure 
development in FDKOSe-NoSeP22 need to be pursued.   
 Brain regions:  Specific brain areas in the male and female DKOSe mice that show signs 
of reactive gliosis and neurodegeneration are the inferior colliculus (IC) and decussation of 
superior cerebellar peduncles (XSCP).  The IC is the principal midbrain nucleus of the auditory 
pathway involved in auditory information processing and sound localization.  The XSCP is 
where motor tract fibers from cerebellar nuclei decussate in the caudal midbrain before 
terminating in the contralateral red nucleus.  Reactive gliosis can be detected as early as 4weeks 
of age in the IC of MDKOSe and neurodegeneration in the IC and XSCP by 10 weeks of age.  
FDKOSe-NoSeP22 mice show reactive gliosis in both the IC and XSCP by 10 weeks of age with 
significant neurodegeneration in the XSCP. 
Brain inhibitory network:  In the brain of DKOSe mice, the brain GABAergic system 
(inhibitory network) has maturation defects.  MDKOSe mice have decreased glutamate 
decarbosylase (GAD67), the enzyme that catalyzes decarboxylation of glutamate to gamma-
amino butyric acid (GABA), which is the most common inhibitory transmitter in the mammalion 
nervous system.  These mice also have decreased density of parvalbumin expressing 
interneurons (PV+IN) (2).  PV is a calcium binding protein found on a subpopulation of 
GABAergic cells.  PV+IN are fast spiking interneurons which control output of principal 
neurons. PV+IN are necessary for fast rhythmic neuronal synchrony and for facilitation of 
information processing during cognitive tasks.   
  As PV+IN mature they become encased by specialized extracellular matrix or agrecan-
enriched perineuronal nets (PNNs) which promote their maturation and synaptic and network 
stability (137).  This maturation process appears to be disrupted in MDKOSe mice, and this 
disruption is preceded by reactive gliosis.  FDKOSe-NoSeP22 mice show reactive gliosis and 
neurodegeneration in the same brain areas as MDKOSe mice which indicates that the same 
neural processes are affected in both males and females.  Further studies investigating the 
GABAergic deficits involved in seizure development would be beneficial in identifying this. 
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Conclusion 
  The aforementioned provides investigational targets for future studies in DKOSe male 
and female mice.  Specific behavioral deficits e.g. motor coordination and weight change, occur 
before seizure onset, allowing deterioration progression to be monitored over a period of time.  
Deficits in GABAergic system maturation in areas of the brain involved in motor coordination 
and auditory processing appear to be the underlying contributory factors.  SeH2O 
supplementation appears to be required during development and adolescent periods but can be 
removed in FDKOSe and castrated MDKOSe mice after P37.   Combined, DKOSe mice could 
potentially serve as a model for the study of ictogenesis and therapeutic drug testing of novel 
drugs for epileptic patients in cases of malnutrition, and to elucidate the compensatory 
mechanisms that are distinct between males and females during development. 
 
80 
 
Rotorod (Age-10weeks)
MW
Tn
Se
MD
KO
Se
MD
KO
Se
-C
as
t-N
oS
eP
37
FW
Tn
Se
FD
KO
Se
FD
KO
Se
-N
oS
eP
37
FD
KO
Se
-N
oS
eP
22
0
50
100
150
200
La
te
nc
y 
to
 fa
ll 
(s
)
(8
 T
ria
l A
ve
ra
ge
)
Rotorod
6wks 7wks 8wks 9wks 10wks
0
50
100
150
MWTnSe
MDKOSe
MDKOSe-Cast-NoSeP37
FWTnSe
FDKOSe
FDKOSe-NoSeP37
FDKOSe-NoSeP22
Age (weeks)
La
te
nc
y 
to
 fa
ll 
(s
)
(8
 T
ria
l A
ve
ra
ge
)
MW
Tn
Se
MD
KO
Se
MD
KO
Se
-C
as
t-N
oS
eP
37
FW
Tn
Se
FD
KO
Se
FD
KO
Se
-N
oS
eP
37
FD
KO
Se
-N
oS
eP
22
0
1000
2000
3000
Av
er
ag
e 
D
is
ta
nc
e 
(c
m
)
ov
er
 5
 m
in
 p
er
io
d
MW
Tn
Se
MD
KO
Se
MD
KO
Se
-C
as
t-N
oS
eP
37
FW
Tn
Se
FD
KO
Se
FD
KO
Se
-N
oS
eP
37
FD
KO
Se
-N
oS
eP
22
0
2
4
6
8
10
Av
er
ag
e 
Sp
ee
d 
(c
m
/s
)
ov
er
 5
 m
in
 p
er
io
d
Audio Open Field (Age-10wks)
Presound Postsound
0
5
10
15
MWTnSe
MDKOSe
FWTnSe
 FDKOSe
FDKOSe-NoSeP22
MDKOSe-Cast-NoSeP37
FDKOSe-NoSeP37
Sp
ee
d 
(c
m
/s
)
% of animals 
that develop 
seizures
% requiring 
euthanasia 
prior to t70
a5KOSe 73-77% 
between t56 
and t70
40%
C5KOSe 83% with SeH2O 
removal at t22
unknown
A B
C D
E F
Figure 5.1: Combined Motor Coordination, Locomotion and Seizure Occurrence Data.  Mean 
latency to fall at ten weeks of age (A), mean latency to fall from six to ten weeks of age (B), 
distance travel (C) and average speed travel (D) in 5 minute period of open field, and speed prior 
to and 10 seconds immediately after start of 85 dB white noise (E) of MWTnSe, MDKOSe, 
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MDKOSe-Cast-NoSeP37, FWTnSe, FDKOSe, FDKOSe-NoSeP37 and FDKOSe-NoSeP22 
mice.  F.  Table of percentage of animals that develop seizures by 10 weeks of age. 
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Figure 5.2: Combined Body Composition Data.  Body (A), brain (B), %ingWAT (C), and 
%gWAT (D) of MWTnSe, MDKOSe, MDKOSe-Cast-NoSeP37, FWTnSe, FDKOSe, FDKOSe-
NoSeP37 and FDKOSe-NoSeP22 mice. 
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